3-P | NOVEL COPY NUMBER ALTERATIONS IN INFANTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA (T-ALL) | Marcela B. Mansur | Received |
6-P | ACUTE LYMPHOBLASTIC LEUKEMIA RECOGNITION BY NATURAL KILLER CELLS: CLINICAL AND THERAPEUTIC IMPLICATIONS | Nadia Peragine | Received |
7-P | K-RASG12D-initiated T-ALL development in mice is accompanied by loss of the wild-type Kras allele | Anna Staffas | Received |
8-P | FREQUENCY AND PROGNOSTIC SIGNIFICANCE OF COPY NUMBER ALTERATIONS (CNA) IN HIGH-RISK B-LINEAGE ADULT ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS ENROLLED IN RISK-ADAPTED PROTOCOLS | Jordi Ribera | Received |
9-P | P38ALPHA/BETA INHIBITION PREVENTS ALL PROLIFERATION IN VIVO | Denis Schewe | Received |
12-P | ANALYSIS OF CRLF2 EXPRESSION IN A COHORT OF 91 NEWLY DIAGNOSED ADULT PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA: CORRELATION WITH CLINICO-BIOLOGICAL FEATURES AND OUTCOME | Fulvia Brugnoletti | Received |
13-P | A CLINICALLY RELEVANT POPULATION OF LEUKEMIC CD34CD19CD58- CELLS IN PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA | Yuan Kong | Received |
17-P | ETV6/RUNX1 TRANSCRIPT IS A POTENTIAL TARGET OF RNA-BINDING PROTEIN IGF2BP1 | Mindaugas Stoskus | Received |
18-P | SNP ARRAY ANALYSIS OF ADULT ALL: A POPULATION BASED STUDY OF LITHUANIAN PATIENTS | Vaidas Dirse | Received |
22-P | PML/RAR-ALPHA INHIBITS PTEN EXPRESSION IN HEMATOPOIETIC CELLS BY COMPETING WITH PU.1 TRANSCRIPTIONAL ACTIVITY | Nelida Ines Ngguera | Received |
26-P | THE GENE SIGNATURE IN C/EBPA DYSFUNCTIONAL AML PREDICTS RESPONSIVENESS TO HDAC INHIBITORS | Meritxell Alberich Jorda | Received |
29-P | THE EFFECT OF ARA-C TREATMENT ON HEMATOPOIETIC STEM CELL EXPANSION AND LEUKEMOGENESIS IN A MOUSE MODEL OF CEBPA MUTANT ACUTE MYELOID LEUKEMIA | monica cimino | Received |
32-P | C/EBPA REGULATES CXCR4 EXPRESSION IN ACUTE MYELOID LEUKEMIA | Yuan-Yeh Kuo | Received |
33-P | COMBINED INHIBITION OF C-KIT AND PI3K/MTOR SIGNALLING HAS SYNERGISTIC ACTIVITY IN C-KIT MUTANT AML | Steven Tinsley | Received |
34-P | THE FUSION GENE NUP98-HOXA9 AS A MODEL FOR LEUKEMOGENESIS: EXPLORING ITS MOLECULAR MECHANISMS AND FUNCTIONAL EFFECTS | ANA RIO-MACHIN | Received |
35-P | ACID CERAMIDASE PROMOTES ACUTE MYELOID LEUKEMIA SURVIVAL THROUGH MCL-1 UPREGULATION | Su-Fern Tan | Received |
36-P | ANTILEUKEMIC EFFECT OF PI3K-MTOR INHIBITORS IN ACUTE MYELOID LEUKEMIA- GENE EXPRESSION PROFILES REVEAL CDC25B EXPRESSION AS DETERMINATE OF PHARMACOLOGICAL EFFECT | Hkon Reikvam | Received |
37-P | L-ASPARAGINASE ALTERS TRANSCRIPTION AND TRANSLATION OF GENES INVOLVED IN METABOLISM IN MYELOID LEUKEMIA | Sung Ah Jun | Received |
38-P | THE TYROSINE KINASE CSK ASSOCIATES WITH FLT3 AND KIT RECEPTORS AND REGULATES DOWNSTREAM SIGNALING IN ACUTE MYELOID LEUKEMIA | Julhash Kazi | Received |
39-P | WHOLE GENOME AND TARGETED BISULFITE SEQUENCING REVEALS 3 DNA METHYLATION CLUSTERS AND NEW BIOLOGICALLY RELEVANT HYPERMETHYLATED GENES IN AML PATIENTS | Hana Hajkova | Received |
40-P | EXPRESSION OF THE SPLICE VARIANT NPM1-R2 HAS STRONGER PROGNOSTIC VALUE THAN NPM1 MUTATIONAL STATUS IN ACUTE MYELOID LEUKEMIA | Malgorzata Zajac | Received |
49-P | EX VIVO PHARMACOLOGICAL EVALUATION OF 16 DRUGS IN 60 ACUTE MYELOID LEUKEMIA PATIENTS USING WHOLE BONE MARROW SAMPLES ANALYZED BY AUTOMATED FLOW CYTOMETRY | Belén Liébana | Received |
50-P | SYSTEMATIC REVIEW AND META-ANALYSIS OF ANTI-CD33 ANTIBODY TREATMENT IN AML GEMTUZUMAB OZOGAMACIN HAS ANTI-LEUKAEMIC EFFICACY | Ching Loke | Received |
51-P | RISK-ADAPTED TRANSPLANT SELECTION ATTENUATES THE NEGATIVE PROGNOSTIC ROLE OF MINIMAL RESIDUAL DISEASE AND GENETIC HIGH RISK FEATURES | Francesco Buccisano | Received |
53-P | ELACYTARABINE / IDARUBICIN IN PATIENTS WITH ACUTE MYELOID LEUKEMIA WHO FAILED CYTARABINE BASED INDUCTION, AND EVALUATION OF THE IMPACT OF THE TRANSPORTER HENT1 ON RESPONSE; RESULTS OF A PHASE II STUDY | Malin Johansen | Received |
56-P | PATTERNS OF RELAPSE IN 169 PATIENTS TREATED WITH ORAL ARSENIC TRIOXIDE DURING INDUCTION AND/OR MAINTENANCE: A 12-YEAR EXPERIENCE | Harinder Gill | Received |
57-P | SURVIVAL IMPACT OF COMPLEX AND MONOSOMAL KARYOTYPE AND LOSS OF CHROMOSOMES 5, 7 AND 17 IN OLDER PATIENTS WITH AML. FIRST EVALUATION OF CYTOGENETIC DATA FROM THE POPULATION BASED SWEDISH AML REGISTRY | Vladimir Lazarevic | Received |
58-P | PATIENTS WITH LATE RELAPSE OF ACUTE MYELOID LEUKEMIA HAVE A HIGH RATE OF DURABLE SECOND COMPLETE REMISSIONS WHEN TREATED WITH CHEMOTHERAPY ONLY | sa Derolf | Received |
59-P | SURVIVAL IN PATIENTS WITH ACUTE MYELOBLASTIC LEUKEMIA IN GERMANY AND THE UNITED STATES: UNEXPLAINED DIFFERENCES IN SURVIVAL IN YOUNG ADULTS | Dianne Pulte | Received |
61-P | LOW- DOSE CHEMOTHERAPY AND DIFFERENTIATING AGENTS AS POST- REMISSION MAINTENANCE PROLONGED DISEASE- FREE AND OVERALL SURVIVAL IN A CASE-CONTROL RETROSPECTIVE STUDY ON POOR PROGNOSIS AML/MDS PATIENTS | Crisŕ Elena | Received |
62-P | A STUDY OF ELACYTARABINE IN RELAPSED OR REFRACTORY AML EVALUATING CARDIAC SAFETY AND PHARMACOKINETIC PROPERTIES | Malin Johansen | Received |
63-P | MULTI-LINEAGE DYSPLASIA AS ASSESSED BY IMMUNO-PHENOTYPE HAS NO IMPACT ON OUTCOME OF ACUTE MYELOID LEUKEMIA WITH MUTATED NUCLEOPHOSMIN (NPM1) | Francesco Mannelli | Received |
65-P | MEDIUM-SIZED FLT3 INTERNAL TANDEM DUPLICATIONS CONFER WORSE PROGNOSIS, THAN SHORT AND LONG DUPLICATIONS | Magdalena Koszarska | Received |
67-P | THERAPY-RELATED MYELOID NEOPLASMS: REPORT OF THE ITALIAN NETWORK ON SECONDARY LEUKEMIAS | LUANA FIANCHI | Received |
68-P | AZACITIDINE FOR RELAPSE TREATMENT IN MYELOID MALIGNANCIES FOLLOWING ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION | Benoit Tessoulin | Received |
69-P | MONITORING MINIMAL RESIDUAL DISEASE IN NPM-1 MUTATED ACUTE MYELOID LEUKEMIA. PRELIMINARY RESULTS AT A SINGLE INSTITUTION | Chiara Pagani | Received |
70-P | THE PROGNOSTIC IMPACT OF ADDITIONAL KARYOTYPIC ABNORMALITIES IN T(8;21) ACUTE MYELOID LEUKEMIA | Zhentang Lao | Received |
71-P | BAALC GENE EXPRESSION REDUCTION DURING INDUCTION PREDICTS OUTCOME IN ACUTE MYELOID LEUKEMIA | vanessa ponziani | Received |
74-P | SUCCESSFUL SALVAGE TREATMENT WITH CLOFARABINE AND CYTARABINE (ARA-C) IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA | alessandra malato | Received |
75-P | ACHIEVING BONE MARROW CLL MINIMAL RESIDUAL DISEASE-FREE STATUS WITH FIRST-LINE FCR IS ASSOCIATED WITH IMPROVED PFS AND CAN BE CONSIDERED A PRIMARY TREATMENT OBJECTIVE | PAOLO STRATI | Received |
76-P | DEVELOPMENT OF A COMPREHENSIVE PROGNOSTIC INDEX PATIENTS WITH CLL | Natali Pflug | Received |
78-P | CHRONIC LYMPHOCYTIC LEUKEMIA CELLS FROM PAIRED LYMPH NODE AND PERIPHERAL BLOOD SHOW A DIFFERENT PATTERN OF COPY NUMBER ABERRATIONS | Silvia Bonina | Received |
80-P | A HIGH NUMBER OF LOSSES IN 11Q CHROMOSOME IS ASSOCIATED WITH SHORT TIME TO FIRST TREATMENT (TFT) AND OVERALL SURVIVAL (OS) IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) | JOSE-ANGEL HERNANDEZ | Received |
81-P | NOTCH1 MUTATED IGHV UNMUTATED CHRONIC LYMPHOCYTIC LEUKEMIA CONSTITUTIVELY OVEREXPRESSED NUCLEOPHOSMIN-1 AND RIBOSOME-ASSOCIATED COMPONENTS | Michele Dal Bo | Received |
82-P | CLL: DIFFERENT AGES, DIFFERENT ANTIGEN RECEPTOR PROFILES | PANAGIOTIS BALIAKAS | Received |
83-P | DETECTION OF TP53 DYSFUNCTION IN CHRONIC LYMPHOCYTIC LEUKEMIA BY AN IN VITRO FUNCTIONAL ASSAY BASED ON TP53 ACTIVATION BY THE NON-GENOTOXIC DRUG NUTLIN-3: A PROPOSAL FOR CLINICAL APPLICATION | Federico Pozzo | Received |
85-P | SEQUENTIAL MRD ANALYSIS IN CLL DEMONSTRATES EXPONENTIAL EXPANSION WITH A PATTERN THAT CANNOT BE PREDICTED FROM PRE-TREATMENT DOUBLING TIME. | Andy Rawstron | Received |
87-P | UNRAVELING THE HETEROGENEITY OF T-CELL PROLYMPHOCYTIC LEUKEMIA (T-PLL) | Anton W. Langerak | Received |
88-P | EPIGENETIC INACTIVATION OF MIR-34B/C IN ADDITION TO MIR-34A AND DAPK1 IN CHRONIC LYMPHOCYTIC LEUKEMIA | Luqian WANG | Received |
91-P | BIALLELIC LOSSES OF 13Q DO NOT CONFER A POORER OUTCOME IN CHRONIC LYMPHOCYTIC LEUKEMIA: ANALYSIS OF 627 PATIENTS WITH ISOLATED 13Q DELETION. | Anna Puiggros | Received |
92-P | A HIGH SENSITIVITY METHOD REVEALED A TWOFOLD-INCREASED INCIDENCE OF NOTCH1 MUTATION WITH ADVERSE PROGNOSTIC IMPACT IN CHRONIC LYMPHOCYTIC LEUKAEMIA | paolo sportoletti | Received |
94-P | NOVEL ASSAY FOR THE IDENTIFICATION OF NOTCH1 PEST DOMAIN MUTATIONS USING FRAGMENT ANALYSIS AND ALLELE SPECIFIC PCR | Paulo Campregher | Received |
95-P | LONG-LASTING RESPONSES TO LENALIDOMIDE AS INITIAL THERAPY OF ELDERLY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA | PAOLO STRATI | Received |
96-P | LOW-DOSE FCR IN ELDERLY/COMORBID PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): UPDATED RESULTS OF PROJECT Q-LITE BY CZECH CLL STUDY GROUP | Luká Smolej | Received |
97-P | PLATINUM AND HIGH-DOSE CYTARABINE-BASED CHEMOTHERAPY IN ULTRA HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA AND RICHTERS SYNDROME: RESULTS OF A RETROSPECTIVE MULTICENTER STUDY | Eric DUROT | Received |
99-P | TOXICITY AND RESPONSE BY COMORBIDITY AND AGE IN A RANDOMIZED STUDY OF ORAL FLUDARABINE AND CYCLOPHOSPHAMIDE WITH RITUXIMAB FIRST-LINE THERAPY OF FIT ELDERLY WITH CHRONIC LYMPHOCYTIC LEUKAEMIA | Stephen Mulligan | Received |
101-P | PRELIMINARY RESULTS FROM A SURVEY OF REAL-LIFE FIRST LINE THERAPY OF CHRONIC LYMPHOCYTIC LEUKAEMIA IN THE UK | Tony Todd | Received |
103-P | INCREASED EXPRESSION OF THE EZH2 METHYLTRANSFERASE AND EVIDENCE OF FUNCTIONALITY IN CLL SUBGOUPS WITH AGGRESSIVE CLINICOBIOLOGICAL PROFILES | Nikos Papakonstantinou | Received |
104-P | OUTCOMES OF PATIENTS WITH FLUDARABINE-REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) A POPULATION-BASED STUDY FROM A WELL-DEFINED GEOGRAPHIC REGION | Sandra Eketorp Sylvan | Received |
105-P | PROLONGED CYTOPENIA RELATED TO FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB IN CHRONIC LYMPHOCYTIC LEUKEMIA | PAOLO STRATI | Received |
106-P | FRONTLINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH DELETION 17P | PAOLO STRATI | Received |
108-P | UPDATED RESULTS OF A PHASE II STUDY OF LENALIDOMIDE AND RITUXIMAB IN RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA. | Miguel Piris-Villaespesa | Received |
110-P | THE PROGNOSTIC VALUE OF THE NUMBER OF CELLS WITH A DELETION OF 13Q14 IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA | Ekaterina Zotina | Received |
113-P | IMATINIB OR DASATINIB TREATMENT OF CHRONIC MYELOID LEUKEMIA REDUCES CIRCULATING MYELOID-DERIVED SUPPRESSOR CELLS AND INCREASES THEIR CD40 EXPRESSION | Stina Sderlund | Received |
114-P | THE AXIS SHP-1/SHP-2 MODULATES VEGFR2 SIGNALING IN CML CELL LINES: VEGFR2 DEREGULATION MAY BE IMPLICATED IN IMATINIB (IMA) RESISTANCE | Nicola Esposito | Received |
115-P | SYNERGY BETWEEN JAK INHIBITOR RUXOLITINIB AND TYROSINE KINASE INHIBITORS (TKIS) TO OVERCOME DRUG RESISTANCE RELATED TO BONE MARROW (BM) STROMA MICROENVIRONMENT IN CHRONIC MYELOID LEUKEMIA (CML) | Concetta Quintarelli | Received |
116-P | CHRONIC MYELOID LEUKEMIA WITH VARIANT T(9;22) REVEALS A DIFFERENT SIGNATURE FROM CASES WITH CLASSIC TRANSLOCATION. | Francesco Albano | Received |
118-P | REDUCED EXPRESSION OF CHIBBY IS A COMPONENT OF BETA-CATENIN ACTIVATION IN CHRONIC MYELOID LEUKEMIA STEM CELLS | Elisa Leo | Received |
119-P | DIFFERENTIAL ACTIVATION OF MTOR KINASE IN CHRONIC AND BLASTIC PHASE OF CHRONIC MYELOGENOUS LEUKEMIA | Tomasz Stoklosa | Received |
120-P | MYELOID-DERIVED SUPPRESSOR CELLS ARE INCREASED IN CHRONIC MYELOID LEUKEMIA AND EXERT IMMUNE SUPPRESSIVE ACTIVITY | Cesarina Giallongo | Received |
121-P | CLINICAL SIGNIFICANCE OF EARLY MOLECULAR RESPONSES IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH FIRST-LINE SECOND-GENERATION TYROSINE KINASE INHIBITORS | Sung-Eun Lee | Received |
122-P | DEEP SEQUENCING OF THE BCR-ABL KINASE DOMAIN REVEALS A FREQUENCY OF 35INS INSERTION/TRUNCATION HIGHER THAN EXPECTED | Caterina De Benedittis | Received |
124-P | A NEW NON CANONICAL ROLE OF IKB ALPHA IN CHRONIC MYELOID LEUKEMIA PATHOGENESIS | Cristina Panuzzo | Received |
125-P | L-AMINO ACID OXIDASE ISOLATED FROM BOTHROPS PIRAJAI INDUCES APOPTOSIS IN BCR-ABL POSITIVE CELLS AND POTENTIATES IMATINIB MESYLATE EFFECT | sandra burin | Received |
126-P | IL-2, IL-12 AND IL-15 PREVENT REACTIVE OXYGEN SPECIES ACCUMULATION ON NATURAL KILLER CELLS FROM CHRONIC MYELOID LEUKEMIA PATIENTS FOLLOWING INTERFERON-ALPHA, IMATINIB AND DASATINIB THERAPY | Paulo Rodrigues Santos | Received |
127-P | EFFECT OF NILOTINIB ON THE FUNCTION OF CAROTID ARTERY ENDOTHELIAL CELLS | mr Gkmen Sevindik | Received |
128-P | STANDARDIZATION OF MRD DETECTION IN CML BY USE OF A PEER GROUP CONVERSION FACTOR | Els Dumoulin | Received |
129-P | BIOLOGICAL CHARACTERISTICS AND DYNAMICS OF BCR-ABL1 MULTIPLE MUTATIONS IN TYROSINE KINASE INHIBITOR RESISTANT CML | Soohyun Kim | Received |
131-P | 10058-F4 A SMALL MOLECULE C-MYC INHIBITOR DECREASES CIP2A AND REDUCES BCR-ABL1 TYROSINE KINASE ACTIVITY IN CHRONIC MYELOID LEUKAEMIA (CML) | CLAIRE LUCAS | Received |
132-P | IMPACT OF DRUG TRANSPORTER ABCG2 HAPLOTYPES IN MOLECULAR RESPONSE OF CML PATIENTS IS MODULATED BY IMATINIB DAILY DOSE | delord marc | Received |
135-P | FIFTEEN-MONTH UPDATE OF A PHASE II TRIAL OF THE COMBINATION OF PEGYLATED INTERFERON ALPHA2ANILOTINIB AS FIRST LINE THERAPY FOR NEWLY DIAGNOSED CHRONIC PHASE CML PATIENTS | Franck Nicolini | Received |
142-P | HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA: RESULTS OF A GERMAN CROSS-SECTIONAL STUDY IN PATIENTS PREVIOUSLY REGISTERED IN PROSPECTIVE, CONTROLLED CLINICAL TRIALS | Susanne Sauele | Received |
144-P | DISCONTINUATION OF BCR-ABL1 TYROSINE KINASE INHIBITOR IN CML PATIENTS WITH UNDETECTABLE MOLECULAR RESIDUAL DISEASE FOR AT LEAST 1 YEAR: INCLUDING UPDATED DATA FROM KIDS STUDY | Yun jeong Oh | Received |
146-P | EFFICACY OF NILOTINIB VERSUS HIGH-DOSE IMATINIB IN EARLY CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS WHO HAVE SUBOPTIMAL MOLECULAR RESPONSES TO STANDARD-DOSE IMATINIB: MULTICENTER RE-NICE STUDY | Soo Young Choi | Received |
147-P | OCT1 GENETIC VARIANTS ARE ASSOCIATED WITH LONG TERM OUTCOMES IN IMATINIB TREATED CML PATIENTS | Maya Koren-Michowitz | Received |
150-P | MECHANISM OF IMPAIRED GLUCOSE METABOLISM DURING NILOTINIB THERAPY IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA | Zdenek Racil | Received |
152-P | FLOW CYTOMETRY EARLY DETECTION OF CD4CD26-CD38 LYMPHOCYTES SUBSET IN LYMPH NODES OF HODGKIN LYMPHOMA | Giuseppe Tagariello | Received |
153-P | FIRST-LINE TREATMENT OF ADVANCED STAGE HODGKIN LYMPHOMA FINAL RESULTS OF A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS | Michaela Rancea | Received |
155-P | A SIMPLE, ACCESSIBLE NEW TOOL TO DEFINE HIGH RISK PATIENTS IN CLASSICAL HODGKIN LYMPHOMA BASED ON VALIDATION OF PRE-EXISTING BIOMARKERS | Paul Greaves | Received |
158-P | ESHAP AS SALVAGE THERAPY FOR RELAPSED OR REFRACTORY HODGKINS LYMPHOMA | Jorge Labrador | Received |
160-P | THE LYMPHOCYTIC HISTOPATHOLOGIC SUBTYPES OF HODGKIN LYMPHOMA (HL): CLINICAL PRESENTATION AND LONG-TERM OUTCOME IN A CASE SERIES OF 61 PATIENTS | Theodoros Vassilakopoulos | Received |
161-P | LONG TERM RESULTS OF MONOCENTRIC PROSPECTIVE STUDY OF VEBEP PLUS RADIOTHERAPY REGIMEN IN NEWLY DIAGNOSED EARLY-UNFAVORABLE STAGE HODGKIN LYMPHOMA | SIMONA PAGLIUCA | Received |
162-P | DEVELOPMENT OF A PROGNOSTIC SCORING SYSTEM FOR PRIMARY REFRACTORY HODGKINS LYMPHOMA TREATED WITH HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION | Marianna David | Received |
163-P | HETEROGENEOUS MANAGEMENT OF ADOLESCENTS AND YOUNG ADULTS WITH HODGKIN LYMPHOMA AND INCONSTANT CONFORMITY OF MEDICAL PRACTICE TO CLINICAL GUIDELINES: EXHAUSTIVE COHORT FROM RHNE-ALPES REGION | Arthur Dony | Received |
166-P | RECURRENT SETBP1 MUTATIONS IN ATYPICAL CHRONIC MYELOID LEUKEMIA | SARA REDAELLI | Received |
168-P | ABERRANT SPLICING DURING ERYTHROID DIFFERENTIATION IN SF3B1 MUTATED SIDEROBLASTIC ANEMIA | Simona Conte | Received |
169-P | RESISTANCE TO APOPTOSIS IN HIGH-RISK MYELODYSPLASTIC SYNDROME CAN BE OVERCOME BY PRO-APOPTOTIC DRUG TREATMENT USING ABT-737 | Stefanie Jilg | Received |
173-P | A PAIR MONOZYGOTIC TWINS WITH CONCORDANT JUVENILE MYELOMONOCYTIC LEUKEMIA: INSIGHT IN THE COURSE OF THE DISEASE | Silvia Bresolin | Received |
174-P | FAMILIAL, NON-ZINC FINGER REGION, GATA2 MUTATED MYELODYSPLASTIC SYNDROME; ASSOCIATED WITH SHORTENED TELOMERE LENGTHS, VIRAL WARTS, PROFOUND MONOCYTE/B/NK CELL DEFICIENCY | Mrinal Patnaik | Received |
175-P | EVALUATION OF PRO-SURVIVAL PATHWAYS, INCLUDED AUTOPHAGY, IN HIGH-RISK MDS BONE MARROW AFTER TREATMENT WITH 5-AZACITIDINE TO RESTORE NORMAL HEMATOPOIESIS | ALESSANDRA ROMANO | Received |
177-P | FLOW CYTOMETRIC CLASSIFICATION OF 350 TYPE III PNH CLONES IN ITALY: A MULTI-CETRIC STUDY | ELISA CANNIZZO | Received |
178-P | CYTOGENETIC CHARACTERIZATION OF CD34 HEMATOPOIETIC PROGENITOR CELLS AND MESENCHYMAL STROMAL CELLS IN MYELODYSPLASTIC SYNDROME (MDS) | Maria Pimenova | Received |
179-P | POLYMORPHISMS IN GENES INVOLVED IN DNA REPAIR AND FOLATE PATHWAY SIGNIFICANTLY IMPACT ON SURVIVAL IN LOW-RISK, UNTREATED MYELODYSPLASIA. | Giuseppe Visani | Received |
183-P | EVALUATION OF A HIGH THROUGHPUT MUTATION-SCREENING STRATEGY IN MYELODYSPLASTIC SYNDROME PATIENTS AND ACUTE MYELOID LEUKEMIA USING TARGETED-GENE ENRICHMENT TECHNOLOGY | Mohsen Karimi Arzenani | Received |
184-P | Impact of 5q Breakpoints on Clinical Outcomes in Patients With IPSS Low/Int-1-Risk Myelodysplastic Syndromes (MDS) and Isolated del(5q) Treated With Lenalidomide in the MDS-004 Study | Gudrun Ghring | Received |
185-P | PROGNOSTIC IMPACT OF DER(1;7) IN MDS IS DIFFERENT FROM DEL(7Q) | Julie Schanz | Received |
186-P | CLINICAL SIGNIFICANCE OF ASXL1 MUTATION IN PATIENTS WITH PRIMARY MYELODYSPLASTIC SYNDROME AND ITS STABILITY DURING DISEASE PROGRESSION | Tsung Chih Chen | Received |
188-P | HIGH DOSES OF ELTROMBOPAG ARE WELL-TOLERATED IN CONJUNCTION WITH AZACITIDINE AND THE COMBINATION DEMONSTRATES ENCOURAGING ACTIVITY IN PATIENTS WITH MDS AND AML. | Michael Dickinson | Received |
195-P | IMPROVED PREDICTIVE PROGNOSTIC POWER OF REVISED-IPSS (IPSS-R) IN A SERIES OF 301 PATIENTS WITH MYELODYSPLASTIC SYNDROME FROM A SINGLE CENTER. | Montserrat Arnan Sangerman | Received |
197-P | HIGH LEVELS OF CEREBLON MESSENGER RNA ARE THE CHARACTERISTIC FEATURE OF LOWER RISK MYELODYSPLASTIC SYNDROMES WITH 5Q DELETION AND ARE CONNECTED WITH THE EFFICACY OF LENALIDOMIDE | Ota Fuchs | Received |
199-P | MORTALITY BURDEN OF TRANSFUSION DEPENDENCY AND IRON OVERLOAD IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES. | Montserrat Arnan Sangerman | Received |
200-P | NOVEL 3Q26 DELETION BONE MARROW FAILURE SYNDROME IN A NEWBORN RESULTING IN DOMINANT NEGATIVE INTERFERENCE OF HEMATOPOIESIS BY TRUNCATED EVI1/MECOM | Lars van der Veken | Received |
202-P | EUROPEAN PATTERN AND IMPACT OF THE USE ERYTHROPOIETIC AGENTS (ESAS)IN LOW AND INT-1 RISK MDS WITH PROPENSITY SCORING TECHNIQUES IN OBSERVATIONAL LONGITUDINAL STUDIES. | Hege Garelius | Received |
204-P | ANTI-MYELOMA ACTIVITY OF A NOVEL ALKYLATING AGENT MELPHALAN-FLUFENAMIDE | Dharminder Chauhan | Received |
205-P | METABOLOMIC PROFILING IDENTIFIES MECHANISMS REGULATING HYPOXIA-INDUCED DRUG RESISTANCE IN MULTIPLE MYELOMA. | Patricia Maiso | Received |
206-P | GENOMIC CHARACTERIZATION OF THE PUTATIVE MULTIPLE MYELOMA STEM CELLS CLONE REVEALS COPY NUMBER ALTERATIONS (CNAS) POSSIBLY CORRELATED WITH THE ORIGIN OF DISEASE | Marina Martello | Received |
207-P | MULTIDIMENSIONAL FLOW CYTOMETRY FOR SENSITIVE EVALUATION OF PATIENTS WITH IGM MGUS OR WALDENSTROMS MACROGLOBULINEMIA AND DIFFERENTIAL DIAGNOSIS WITH OTHER LYMPHOMAS | Bruno Paiva | Received |
208-P | IDENTIFICATION OF SERUM MICRORNA PROFILE IN MULTIPLE MYELOMA ASSOCIATED WITH COMPLETE REMISSION AND PROGRESSION AFTER AUTOLOGOUS STEM-CELL TRANSPLANTATION | Carlos Fernández de Larrea | Received |
209-P | IMPROVED ACCURACY OF DISCRIMINATION BETWEEN IGM MULTIPLE MYELOMA (MM) AND WALDENSTROEMS MACROGLOBULINAEMIA (WM) BY TESTING FOR MYD88 L265P MUTATIONS | Wolfgang Willenbacher | Received |
210-P | ABT-199 IS HIGHLY EFFECTIVE AGAINST MULTIPLE MYELOMA AND PLASMA CELL LEUKEMIA HARBORING T(11;14) TRANSLOCATION | Cyrille Touzeau | Received |
214-P | MULTIDIMENSIONAL FLOW CYTOMETRY IMMUNOPHENOTYPIC QUANTIFICATION AND CHARACTERIZATION OF IN VIVO MESENCHYMAL STEM CELLS IN MGUS AND MULTIPLE MYELOMA | Rui Leite | Received |
216-P | AN EGFP IMAGING BASED IN VIVO MODEL FOR STUDYING THE BIOLOGY AND TREATMENT OF MULTIPLE MYELOMA | lisha ai | Received |
217-P | IDENTIFICATION OF POTENTIAL DRUG TARGETS WITHIN THE UBIQUITIN PROTEASOME SYSTEM IN MULTIPLE MYELOMA | Lisa Crawford | Received |
218-P | MULTIPARAMETER FLOW CYTOMETRY DETECTION OF CLONAL PLASMA CELLS IN THE BONE MARROW OF PATIENTS WITH SOLITARY PLASMACYTOMA DETERMINES THE RISK OF PROGRESSION TO ACTIVE MYELOMA | Bruno Paiva | Received |
219-P | CAN IMMUNOPHENOTYPIC CR BE ALSO ACHIEVED IN RELAPSED MULTIPLE MYELOMA PATIENTS? | Bruno Paiva | Received |
220-P | MYELOMA PLASMA CELLS ALTER THE BONE MICROENVIRONMENT BY STIMULATING AN INCREASE IN MESENCHYMAL STEM CELL NUMBERS | Jacqueline Noll | Received |
221-P | EFFICACY AND SAFETY OF 3 LENALIDOMIDE-BASED COMBINATIONS IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: RESULTS FROM THE PHASE 3 COMMUNITY BASED EMN01 TRIAL | Francesca Gay | Received |
223-P | BORTEZOMIB-THALIDOMIDE-DEXAMETHASONE VERSUS THALIDOMIDE-DEXAMETHASONE PLUS AUTOTRANSPLANTATION FOR MULTIPLE MYELOMA: UPDATED FOLLOW-UP AND OUTCOMES AFTER RELAPSE IN THE PHASE 3 GIMEMA-MMY-3006 TRIAL | paola tacchetti | Received |
226-P | MM-005: A PHASE 1 TRIAL OF POMALIDOMIDE, BORTEZOMIB, AND LOW-DOSE DEXAMETHASONE (PVD) IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM) | Paul Richardson | Received |
227-P | TANDEM AUTOLOGOUS/ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATIONS IN FIRST LINE HIGH RISK MULTIPLE MYELOMA PATIENTS: EVOLVING STRATEGIES WITH THE IMMUNOMODULATING DRUGS | Mauricette Michallet | Received |
231-P | BENDAMUSTINE, BORTEZOMIB AND DEXAMETHASONE (BVD) IN ELDERLY MM PROGRESSIVE AFTER 1ST LINE THERAPY (IFM 2009-01 TRIAL): PREDICTIVE FACTORS OF DEFAVOURABLE OUTCOME | Philippe Rodon | Received |
235-P | A COMPARISON BETWEEN NEXT-GENERATION SEQUENCING AND ASO-QPCR FOR MINIMAL RESIDUAL DISEASE DETECTION IN MULTIPLE MYELOMA | Hiroyuki Takamatsu | Received |
241-P | IMPACT OF HISTORY OF AUTOIMMUNE DISEASE ON SURVIVAL IN MULTIPLE MYELOMA AND MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE | Ebba Lindqvist | Received |
242-P | LOW RATE OF SECONDARY PRIMARY MALIGNANCIES (SPMS) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS TREATED WITH LENALIDOMIDE: FIRST RESULTS FROM THE MRC MM XI TRIAL | Annamaria Brioli | Received |
243-P | THERAPY FOLLOWING RELAPSE ON MELPHALAN-PREDNISONE-LENALIDOMIDE (LEN) FOLLOWED BY LEN MAINTENANCE IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: EFFICACY AND SAFETY OF SECOND LINE LEN IN MM-015 | Meletios Dimopoulos | Received |
244-P | ANALYSIS OF MM-003 PATIENTS WITH MODERATE RENAL IMPAIRMENT USING POMALIDOMIDE LOW-DOSE DEXAMETHASONE (POM LODEX) VS. HIGH-DOSE DEXAMETHASONE (HIDEX) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) | Katja Weisel | Received |
245-P | SALVAGE TREATMENT WITH POMALIDOMIDE-CYCLOPHOSPHAMIDE-PREDNISONE PRODUCES SIMILAR OUTCOMES AS COMPARED TO PRIOR THERAPIES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA | Alessandra Larocca | Received |
248-P | A MOUSE MODEL FOR HUMAN MYELOFIBROSIS | IOANNA TRIVIAI | Received |
249-P | DEREGULATED MIRNAS IN JAK2V617F-NEGATIVE ESSENTIAL THROMBOCYTHEMIA PATIENTS TARGET SOCS FAMILY MEMBERS | Beatriz Bellosillo | Received |
250-P | A DIFFERENTIAL CENTROSOME LOCALIZZATION OF WILD TYPE (WT) AND JAK2V617F PROTEIN IN HUMAN LEUKEMIA CELL LINES | Biagio De Angelis | Received |
251-P | EVALUATION OF THROMBIN GENERATION POTENTIAL IN POLYCYTHEMIA VERA PATIENTS ENROLLED IN THE CYTO-PV ITALIAN CLINICAL TRIAL | Marina Marchetti | Received |
253-P | A TRANSLOCATION T(3 ;13)(Q13 ;Q12) FUSES FLT3 TO A NOVEL PARTNER GENE, GOLGB1, IN A MYELOID/LYMPHOID NEOPLASM WITH EOSINOPHILIA. | Estelle TROADEC | Received |
255-P | INCREASED PREVALENCE OF AUTOIMMUNE PHENOMENA IN MYELOFIBROSIS: RELATIONSHIP WITH CLINICAL AND MORPHOLOGICAL CHARACTERISTICS, AND WITH IMMUNOREGULATORY CYTOKINE PATTERNS | Francesca Guidotti | Received |
257-P | ALL-TRANS RETINOIC ACID POTENTIATES THE INHIBITORY EFFECTS OF INTERFERON ALPHA (IFN) ON CHRONIC MYELOPROLIFERATIVE NEOPLASMS (MPN) PROGENITORS IN VITRO. | Novella Pugliese | Received |
258-P | SETBP1 OVEREXPRESSION IN CLASSICAL BCR/ABL1-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS | Francesco Albano | Received |
259-P | CUSTOM AMPLICON CAPTURE AND BENCH-TOP HIGH THROUGHPUT SEQUENCING TO SCREEN FOR MUTATIONS ASSOCIATED WITH MYELOPROLIFERATIVE NEOPLASMS | Gareth Gerrard | Received |
260-P | QUANTITATIVE RT-PCR FOR PDGFR IS USEFUL FOR DIAGNOSIS AND MOLECULAR MONITORING OF PATIENTS WITH PDGFR REARRANGEMENTS TREATED WITH TYROSINE-KINASE INHIBITORS | Eric Lippert | Received |
261-P | CHARACTERIZATION OF PLATELET HYPERCOAGULABILITY IN HIGH-HEMATOCRIT POLYCYTHEMIA VERA PATIENTS | Marina Marchetti | Received |
262-P | CHARACTERIZATION OF MUTATIONS IN ASXL1, SRSF2, CBL AND JAK2 GENES IN CHRONIC MYELOMONOCYTIC LEUKEMIA | Laura Palomo | Received |
263-P | ADDITIONAL MUTATIONS TARGETING GENES UNRELATED TO RAS PATHWAY ARE FOUND IN SPORADIC JMML BUT NOT IN SYNDROMIC JMML | Aurélie Caye | Received |
264-P | DETECTION OF LEUKEMIA-ASSOCIATED MUTATIONS IN HEMATOLOGICALLY NORMAL ELDERLY INDIVIDUALS | Joannah Score | Received |
265-P | THE IDENTIFICATION OF A PSTAT5 GENE SIGNATURE AND ITS MODULATION IN RUXOLITINIB PHARMACODYNAMIC RESPONSE IN HEMATOLOGIC MALIGNANCY | Jessica Litvan | Received |
266-P | DO MYELOPROLIFERATIVE NEOPLASMS (MPNS) HAVE STAGES? ANALYSIS OF RELATIONSHIP OF DISEASE DURATION, PROGNOSTIC SCORES, AND SYMPTOMATIC BURDEN OF 1467 MPN PATIENTS | Holly Geyer | Received |
268-P | MUTATIONS IN THE RNA SPLICING MACHINERY GENES IN MYELOFIBROTIC TRANSFORMATION OF ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA | Beatriz Bellosillo | Received |
269-P | MULTIVARIATE ANALYSIS OF THE ASSOCIATION OF CYTOKINE LEVELS AND REDUCTIONS IN SPLEEN SIZE IN COMFORT-II, A PHASE 3 STUDY COMPARING RUXOLITINIB TO BEST AVAILABLE THERAPY (BAT) | Jessica Litvan | Received |
270-P | SPLICEOSOME COMPONENT MUTATIONS AND CYTOGENETIC CORRELATES IN WORLD HEALTH ORGANIZATION (WHO)-DEFINED CHRONIC MYELOMONOCYTIC LEUKEMIA | Sameer Parikh | Received |
271-P | ACQUIRED COPY-NEUTRAL LOSS OF HETEROZIGOSITY OF CHROMOSOME 1P AS A MOLECULAR EVENT ASSOCIATED WITH MARROW FIBROSIS IN MPL MUTATED MYELOPROLIFERATIVE NEOPLASMS | elisa rumi | Received |
273-P | MYELOPROLIFERATIVE NEOPLASM QUALITY OF LIFE (MPN-QOL) STUDY GROUP: DUAL SERIAL ASSESSMENT STUDIES FOR IMPACT OF STANDARD THERAPEUTIC APPROACHES IN MPN POPULATIONS (MEASURE AND SYMPTOMS TRIALS) | Holly Geyer | Received |
274-P | LONG-TERM EFFICACY AND SAFETY OF CLADRIBINE (2-CDA) IN ADULT PATIENTS WITH MAST CELL DISEASE : A FRENCH MULTICENTER STUDY OF 68 PATIENTS | stephane BARETE SB | Received |
275-P | CIRCULATING YKL-40 IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA (ET) AND POLYCYTHEMIA VERA (PV) TREATED WITH THE NOVEL HISTONE DEACETYLASE INHIBITOR VORINOSTAT | Christen Andersen | Received |
276-P | IMPACT OF HEMATOCRIT ON SYMPTOM BURDEN AMONG POLYCYTHEMIA VERA PATIENTS | Robyn Emanuel | Received |
277-P | WHITE BLOOD CELLS COUNT INFLUENCE THE PROGNOSIS OF POLYCYTHEMIA VERA PATIENTS: A SUB-ANALYSIS OF THE CYTO-PV STUDY. | RICCARDO CAVAZZINA | Received |
278-P | Safety Overview of Phase 1-2 Studies of Pacritinib, a Non-Myelosuppressive JAK2/FLT3 inhibitor, in Patients with Hematological Malignancies | Kristin MacIntosh | Received |
279-P | A PHASE II STUDY OF VORINOSTAT (MK-0683) IN PATIENTS WITH PRIMARY MYELOFIBROSIS (PMF) AND POST-POLYCYTHAEMIA VERA MYELOFIBROSIS (PPV-MF) | Christen Andersen | Received |
280-P | CLINICAL FEATURES OF ESSENTIAL THROMBOCYTHEMIA WITH SPLEEN ENLARGEMENT: THE EXPERIENCE OF LAZIAL GROUP FOR THE STUDY OF SMPC, PH-. | Alessandro Andriani | Received |
284-P | DETECTION OF PERIPHERAL BLOOD MONOCLONAL T LYMPHOCYTOSIS AND RISK OF T LYMPHOPROLIFERATIVE DISEASE DEVELOPMENT | Giuseppe Tagariello | Received |
286-P | VITAMIN D3 AND LENALIDOMIDE SYNERGIZE TO INDUCE APOPTOSIS IN MANTLE CELL LYMPHOMA VIA DEMETHYLATION OF BIK | Carole Brosseau | Received |
288-P | THE HOST GENETIC BACKGROUND MODULATES TREATMENT ACTIVITY AND TOXICITY IN FOLLICULAR LYMPHOMA: FIL-FOLL05 TRIAL | Giuseppe Palumbo | Received |
292-P | MYD88 L265P MUTATION IN WALDENSTROM MACROGLOBULINEMIA : INCIDENCE AND FUNCTIONAL STUDY | Stephanie Poulain | Received |
294-P | B-CELL REPERTOIRE ANALYSIS OF INDOLENT MCL WITH SPLENIC PRESENTATION : A DISTINCT ONTOGENY FROM CLASSICAL MCL? | clémentine sarkozy | Received |
296-P | INFLUENCE OF THE B-CELL RECEPTOR (BCR) SIGNALING PATHWAYS ON CD20 LEVELS IN TUMOR CELLS AND ANTITUMOR ACTIVITY OF ANTI-CD20 MONOCLONAL ANTIBODIES | Magdalena Winiarska | Received |
297-P | GENETIC VARIATION IN INTERFERON REGULATORY FACTOR 4 AND INTERLEUKIN 10 GENES, AND THE RISK FOR DIFFUSE LARGE B-CELL LYMPHOMA | In-Suk Kim | Received |
298-P | PROGNOSTIC IMPACT OF EZH2 EXPRESSION, H3K27 TRIMETHYLATION AND DNA METHYLATION IN DIFFUSE LARGE B CELL LYMPHOMA | Shih-Chiang Lin | Received |
299-P | BMI1 EXERTS ITS ONCOGENIC EFFECTS VIA ENHANCEMENT OF ANTI-APOPTOTIC POTENTIAL IN MANTLE CELL LYMPHOMA | kazuaki teshima | Received |
300-P | THE ROLE OF CXCCHEMOKINE IL-8, IL-6 AND CXCR2 RECEPTOR IN LYMPHOPLASMACYTIC LYMPHOMA: CORRELATIONS WITH MICROVASCULAR CHARACTERISTICS AND CLINICAL FEATURES | Georgia Levidou | Received |
301-P | HIV STATUS DOES NOT INFLUENCE THE OUTCOME OF PATIENTS DIAGNOSED WITH DLBCL TREATED WITH R-CHOP IN THE HAART ERA | Rita Coutinho | Received |
302-P | Upfront allogenic stem cell transplantation in patients with advanced T-cell lymphomas : an intention-to-treat analysis from a single institution | Marion Loirat | Received |
304-P | R-CHOP21 VS R-CHOP14 IN 1024 DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: RESULTS FROM A MULTICENTRE RETROSPECTIVE STUDY OF FONDAZIONE ITALIANA LINFOMI (FIL) | Luigi Rigacci | Received |
305-P | SINGLE-AGENT LENALIDOMIDE IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: A COMBINED ANALYSIS FROM THE MCL-001, NHL-002, AND NHL-003 STUDIES | Marybeth McKenzie | Received |
307-P | INFERIOR OUTCOME OF ELDERLY DLBCL PTS WITH 25-OH VITAMIN D DEFICIENCY TREATED WITH CHOP PLUS RITUXIMAB: RESULTS OF THE RICOVER-60 TRIAL OF THE GERMAN HIGH-GRADE NON-HODGKIN LYMPHOMA STUDY GROUP DSHNHL | Jrg Thomas Bittenbring | Received |
310-P | PIXANTRONE MONOTHERAPY IN HISTOLOGICALLY CONFIRMED, RELAPSED OR REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA: POST HOC ANALYSIS FROM A PHASE III TRIAL | Arthur Smyth Medina | Received |
311-P | SOX11 CAN BE USED AS A LONGITUDINAL MINIMAL RESIDUAL DISEASE MARKER FOR MANTLE CELL LYMPHOMA | Anita Simonsen | Received |
312-P | CONTRIBUTION OF CEREBROSPINAL FLUID SCD19 LEVELS TO THE DETECTION OF CNS LYMPHOMA: IMPACT ON DISEASE OUTCOME | Lourdes Martin Martin | Received |
313-P | RITUXIMAB-PECC FOLLOWED BY 90Y-IBRITUMOMAB TIUXETAN CONSOLIDATION IN RELAPSED OR REFRACTORY DLBCL PATIENTS WHO ARE NOT ELIGIBLE FOR OR AFTER ASCT: PRELIMINARY RESULTS FROM A PHASE II HOVON STUDY | Pieternella Lugtenburg | Received |
316-P | EFFICACY OF NON-PEGYLATED LIPOSOMAL DOXORUBICIN IN ELDERLY PATIENTS WITH AGGRESSIVE B-CELL NON HODGKIN LYMPHOMA: A MULTICENTRIC STUDY. | Federica Loscocco | Received |
317-P | THE ROLE OF PET/CT AFTER RITUXIMAB-CHOP (R-CHOP) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): RESPONSE ASSESSMENT, PROGNOSTIC SIGNIFICANCE AND IMPLICATIONS FOR SUBSEQUENT RADIOTHERAPY (RT) | Theodoros Vassilakopoulos | Received |
319-P | THE LYMPHOCYTES TO MONOCYTES RATIO IDENTIFIES A PATIENT SUBGROUP AMONG HIGH RISK DLBCL THAT MAY BENEFIT FROM UPFRONT INTENSIVE TREATMENT WITH AUTOGRAFT | Anna Maria Barbui | Received |
321-P | NON-INTERVENTIONAL STUDY BE-1ST: FIRST LINE THERAPY WITH BENDAMUSTINE IN ADVANCED INDOLENT NON-HODGKIN LYMPHOMA (NHL) IN TREATMENT ROUTINE | Tessa Schliephacke | Received |
322-P | THE PROGNOSTIC ROLE OF EBV IN PERIPHERAL BLOOD OF PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA | Maria Chiara Tisi | Received |
324-P | LYMPHOMAS WITH MYC-TRANSLOCATION OTHER THAN BURKITTS: BAD PROGNOSIS DESPITE SPECIFIC IMMUNOCHEMOTHERAPY FOR BURKITTS LYMPHOMA | José Tomás Navarro | Received |
326-P | THE POTENTIAL OF CD127 AS A PROGNOSTIC AND RESIDUAL DISEASE MARKER IN CHRONIC ADULT T CELL LEUKEMIA/LYMPHOMA. | Huseini Kagdi | Received |
327-P | EVALUATION OF THE PROGNOSTIC SIGNIFICANCE OF THE BODY MASS INDEX (BMI) IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) RECEIVING RITUXIMAB-CHOP (R-CHOP) OR SIMILAR IMMUNOCHEMOTHERAPY | Theodoros Vassilakopoulos | Received |
328-P | AIDS-RELATED LYMPHOMAS (ARL), OUTCOME AND PROGNOSTIC FACTORS | TERESA GARRIDO | Received |
330-P | THE USE OF SYSTEMIC THERAPY DOES NOT IMPROVE THE RESULTS OF LOCOREGIONAL TREATMENT IN LIMITED STAGE (I-II) FOLLICULAR LYMPHOMA: STUDY OF 112 PATIENTS. | Juan-Manuel Sancho | Received |
332-P | CLINICAL AND MOLECULAR SIGNIFICANCE OF TUMOR NECROSIS IN NEWLY DIAGNOSED PATIENTS WITH HODGKINS LYMHOMA AND DIFFUSE LARGE B CELL LYMPHOMA | Ihab Abd el rahman | Received |
335-P | CLINICAL RELEVANCE OF INTERNATIONAL PROGNOSTIC INDEX AS A PREDICTOR FOR VENOUS THROMBOEMBOLISM IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: RESULTS OF A SINGLE CENTER PROSPECTIVE COHORT STUDY | Sung Hee Lim | Received |
338-P | LOWER INCIDENCE OF EBV-POSITIVITY IN ELDERLY DIFFUSE LARGE B-CELL LYMPHOMA: POSSIBLE NEW SUBGROUP OF ELDERLY B-CELL LYMPHOMA | Tatsuki Tomikawa | Received |
341-P | UTILITY OF F-18 FDG PET/CT FOR THE DIAGNOSIS AND THERAPEUTIC MANAGEMENT FOR EXTRANODAL NATURAL KILLER (NK)/T CELL LYMPHOMA, NASAL TYPE | Bing Xu | Received |
344-P | LONG TERM SURVEY OF 180 PATIENTS TRANSPLANTED AFTER RIC REGIMEN USING THREE DOSES OF ATG: A BELGIAN HEMATOLOGY SOCIETY (BHS) NATIONAL PROSPECTIVE TRIAL | Dominique Bron | Received |
345-P | SPECTRUM OF EPSTEIN-BARR VIRUS-ASSOCIATED DISEASES IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION | Qifa Liu | Received |
346-P | ENTERAL VERSUS PARENTERAL NUTRITIONAL SUPPORT POST ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION RESULTS OF A RANDOMIZED CONTROLLED TRIAL | Sarah Andersen | Received |
347-P | COMBINED CMV REPLICATION AND CHRONIC GVHD GENERATE A SIGNIFICANT SYNERGY OF ANTI-LEUKEMIC EFFECT AFTER ALLOGENEIC HSCT IN ACUTE MYELOID LEUKEMIA | Ji Eun Jang | Received |
348-P | HUMAN HERPESVIRUS-6 REACTIVATION AND HHV-6 ENCEPHALITIS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A MULTICENTER, PROSPECTIVE STUDY. | Masao Ogata | Received |
349-P | CENTRAL NERVOUS SYSTEM (CNS) RELAPSE IN AML PATIENTS WITH CNS DISEASE UNDERGOING ALLOGENIC STEM CELL TRANSPLANTATION- RISK FACTORS AND PROGNOSIS | Mrinal Patnaik | Received |
350-P | COMPARISON OF MESENCHYMAL STEM CELLS AND MESENCHYMAL STEM CELLS COMBINED WITH CORD BLOOD FOR TREATMENT OF ENGRAFT FAILURE FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION: A PROSPECTIVE PI | Qifa Liu | Received |
351-P | ABCG2 OVEREXPRESSION NEGATIVELY AFFECT OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANT IN ACUTE MYELOID LEUKEMIA PATIENTS | Mario Tiribelli | Received |
353-P | A LEBANESE-ITALIAN COLLABORATIVE INITIATIVE ON BONE MARROW TRANSPLANTATION IN PEDIATRIC PATIENTS WITH ?-THALASSEMIA MAJOR | Hussein Abbas | Received |
356-P | CIDOFOVIR AS SECOND LINE THERAPY IN CMV REACTIVATION: CLINICAL AND BIOLOGICAL CORRELATES. | Francesca Farina | Received |
357-P | IS IMATINIB MAINTENANCE REQUIRED FOR PATIENTS WITH RELAPSE CHRONIC MYELOID LEUKEMIA POST-TRANSPLANTATION OBTAINING CMR? A PILOT RETROSPECTIVE INVESTIGATION | Qifa Liu | Received |
359-P | UNRELATED CORD BLOOD TRANSPLANTATION FOR CENTRAL NERVOUS SYSTEM RELAPSE IN HIGH RISK ACUTE LYMPHOBLASTIC LEUKEMIA | Changcheng Zheng | Received |
360-P | LENOGRASTIM FROM DAY 7 AND PEGFILGRASTIM ARE EQUALLY EFFECTIVE IN REDUCING TIME TO NEUTROPHIL ENGRAFTMENT, ANTIBIOTIC USE AND INPATIENT STAY IN PATIENTS WITH MYELOMA UNDERGOING AUTOLOGOUS TRANSPLANT | Benjamin Bailiff | Received |
361-P | TWO DIFFERENT PLERIXAFOR STEM CELL MOBILIZATION STRATEGIES. A MULTICENTER EXPERIENCE. | CARMEN ALBO | Received |
364-P | DONOR AND RECIPIENT STR ANALYSIS BEFORE ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION: POSSIBLE CORRELATION WITH POST-TRANSPLANT OUTCOME | Sabrina Giammarco | Received |
365-P | COMPARISON BETWEEN LONG-TERM AND SHORT-TERM ADMINISTRATION OF ITRACONAZOLE FOR PRIMARY ANTIFUNGAL PROPHYLAXIS IN ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION: A MULTICENTER, RANDOMIZED TRIAL | Qifa Liu | Received |
366-P | BENDAMUSTINE, ETOPOSIDE, CYTARABINE AND MELPHALAN (BEEAM) FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION INDUCE LONG-LASTING COMPLETE REMISSIONS IN A HIGH PROPORTION OF RESISTANT/RELAPSED LYMPHOMA PATIENTS: 32 MONTHS FOLLOW-UP UPDATE. | Alessandro Isidori | Received |
367-P | A CONDITIONING PLATFORM WITH FLUDARABINE, BUSULFAN AND ATG CONDUCTS TO IDENTICAL PROMISING RESULTS IN PATIENTS UNDERGOING ALLOGENEIC TRANSPLANTATION FROM BOTH MATCHED AND MISMATCHED UNRELATED DONOR | devillier raynier | Received |
368-P | MOLECULAR MONITORING AND STEPWISE PREEMPTIVE THERAPY FOR EPSTEIN-BARR VIRUS VIREMIA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION | Qifa Liu | Received |
371-P | REDUCED TOXICITY CONDITIONING AND ALLOGENEIC STEM CELL TRANSPLANTATION IN ADULTS USING FLUDARABINE, BCNU, MELPHALAN, AND ANTITHYMOCYTE GLOBULIN (FBM-A): OUTCOMES DEPEND ON DISEASE RISK INDEX | Jose Leis | Received |
373-P | PREDICTION OF MOBILIZATION FAILURE FOR PRE-EMPTIVE PLERIXAFOR ADMINISTRATION: THE PAMPLONA PROTOCOL | AMAYA ZABALZA | Received |
374-P | DOES ALLOGENEIC STEM CELL TRANSPLANTATION OVERCOME THE ADVERSE RISK OF FLT3 POSITIVIVITY IN CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKAEMIA? | Sorcha Ni Loingsigh | Received |
376-P | RITUXIMAB-BASED TREATMENTS FOLLOWED BY ADOPTIVE CELLULAR THERAPIES FOR POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE IN RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION | Qifa Liu | Received |
378-P | A GENETIC VARIANT IN THE CD53 INTRON FUNCTIONALLY PREDICTS TRANSPLANT OUTCOMES AFTER HLA-MATCHED UNRELATED BONE MARROW TRANSPLANTATION | Akiyoshi Takami | Received |
379-P | RELATIONSHIP BETWEEN INFUSION FEVER FOLLOWING PERIPHERAL BLOOD STEM CELL AND PERI-ENGRAFTMENT SYNDROME IN PEADIATRIC PATIENTS UNDERGOING HAPLOIDENTICAL ALLOGENEIC STEM CELL TRANSPLANTATION | YAO CHEN | Received |
381-P | STENOTROPHOMONAS MALTOPHILIA INFECTION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION -RISK FACTORS AND THERAPEUTIC STRATEGIES- | Shiratori Souichi | Received |
387-P | ERYTHROPOIETIN IMPROVES BRAIN DEVELOPMENT IN SHORT-TERM HY0POXIA IN RAT EMBRYO CULTURES | Yasemin Altuner Torun | Received |
388-P | DISULFIRAM/COPPER COMPLEX COULD ELIMINATE RAJI CELLS IN VITRO AND VIVO THROUGH ACTIVATION OF OXIDATIVE STRESS AND INHIBITION OF NRF2 AND NF-?B | Bing Xu | Received |
391-P | THE SAFETY PROFILE OF DEFERASIROX REMAINS CONSISTENT AS NON-TRANSFUSION-DEPENDENT THALASSEMIA PATIENTS APPROACH THE TARGET LIVER IRON CONCENTRATION OF 3 MG FE/G DW FOR INTERRUPTING CHELATION | Germanicus Hansa-Wilkinson | Received |
392-P | PROGNOSTIC CMR PARAMETERS FOR HEART FAILURE AND ARRHYTHMIAS IN A LARGE COHORT OF WELL TREATED THALASSEMIA MAJOR PATIENTS | Antonella Meloni | Received |
393-P | IMPACT OF MONITORING WITH LIVER MRI-R2 ON LIVER IRON BURDEN AND DEVELOPMENT OF ENDOCRINOPATHIES: A RETROSPECTIVE AUDIT | Stephanie Ko | Received |
394-P | MYOCARDIAL FIBROSIS BY CMR LGE IN A LARGE COHRT OF PEDIATRIC THALASSEMIA MAJOR PATIENTS | Antonella Meloni | Received |
395-P | CMR SURVEY IN A LARGE COHORT OF TI PATIENTS CATEGORIZED IN DIFFERENT TRANSFUSIONAL REGIMENS | Antonella Meloni | Received |
396-P | EVALUATION OF GLYCAEMIC ABNORMALITIES IN ?ETA THALASSEMIA MAJOR USING CONTINUOUS GLUCOSE MONITORING SYSTEM AND ORAL GLUCOSE TOLERANCE TEST | Mohamed AbdelDaem Mohamed Yassin | Received |
398-P | EFFECTS OF THE ANTI RANK LIGAND DENUSOMAB ON BETA THALASSEMIA MAJOR-INDUCED OSTEOPOROSIS | Mohamed AbdelDaem Mohamed Yassin | Received |
399-P | REFERENCE RANGES FOR BIVENTRICULAR VOLUMES AND EJECTION FRACTION AND FOR LEFT VENTRICULAR MASS IN ADULT THALASSEMIA INTERMEDIA PATIENTS WITHOUT MYOCARDIAL IRON OVERLOAD | Antonella Meloni | Received |
400-P | CLINICAL EVOLUTION IN FOUR CARRIERS OF BETA GLOBIN LOCUS DELETIONS | Felix De la Fuente | Received |
401-P | PITUITARY MRI IN CORRELATION WITH IRON OVERLOAD AND HYPOGONADISM IN YOUNG THALASSEMIA MAJOR PATIENTS | Amira Adly | Received |
402-P | HBH CONSTANT SPRING DISEASE (HBHCS) HAS LOWER SERUM FERRITIN RELATIVE TO LIVER IRON CONCENTRATION (LIC) COMPARED TO DELETIONAL HBH DISEASE: IMPORTANCE OF LIC MEASUREMENT IN HBHCS | Ai Leen Ang | Received |
403-P | AN AUTOMATIC METHOD FOR MYOCARDIAL T2 CURVE FITTING IN THALASSEMIA PATIENTS WITH SEVERE IRON OVERLOAD | Antonella Meloni | Received |
404-P | MOVEMENT ABNORMALITIES IN THE LEFT VENTRICLE OF THALASSEMIA MAJOR PATIENTS | Antonella Meloni | Received |
406-P | Mortality sickle cell diseaserisk factors in a Dutch cohort | Marein Schimmel | Received |
407-P | PRASUGREL IN CHILDREN WITH SICKLE CELL DISEASE: PHARMACOKINETIC AND PHARMACODYNAMIC CHARACTERISTICS FROM AN OPEN-LABEL, ADAPTIVE-DESIGN, DOSE-RANGING STUDY | Julie Sherman | Received |
410-P | NEWBORN SCREENING FOR SICKLE CELL DISEASE IN BRUSSELS, A PROGRAM WITH AN ONGOING CLINICAL OUTCOME IMPROVEMENT | Phu-Quoc L | Received |
411-P | ENDOTHELIAL NITRIC OXIDE SYNTHASE GENE INTRONE4 VNTR POLYMORPHISM IN SICKLE CELL DISEASE AND TRANSFUSION-DEPENDENT ?-THALASSEMIA MAJOR: RELATION TO CARDIO-VASCULAR COMPLICATIONS | Azza Tantawy | Received |
412-P | ANTENATAL SCREENING PROGRAMME FOR HAEMOGLOBINOPATHY IN A LOW PREVALENCE AREA: IS IT EFFECTIVE? | ANANDIKA LIYANAGE | Received |
413-P | FG4592, A NOVEL INHIBITOR OF THE PROLYL HYDROXYLASE OF HYPOXIA-INDUCIBLE FACTOR (HIF-PH) ELICITED LINEAR-EXPONENTIAL DOSE-RESPONSE PROFILE ON PLASMA ERYTHROPOIETIN (EPO) LEVELS | Xia Chen | Received |
415-P | DEVELOPMENT OF A LABORATORY PATHWAY TO ASSIST THE DIAGNOSIS OF HEREDITARY HAEMOCHROMATOSIS IN PRIMARY CARE | Catherine Ogilvie | Received |
418-P | INTRAVENOUS IRON THERAPY FOR TREATMENT OF ANEMIA DURING PREGNANCY IS ASSOCIATED WITH IMPROVED MATERNAL QUALITY OF LIFE, LESS POSTNATAL DEPRESSION AND LONGER BREASTFEEDING | Alhossain Khalafallah | Received |
420-P | STUDY OF IRON STATUS AS A CONTRIBUTING FACTOR TO ANEMIA IN PEDIATRIC CANCER PATIENTS | Azza Tantawy | Received |
424-P | FOUR MEASURES TO REDUCE THE RATE OF HEALTH CARE-ASSOCIATED BLOODSTREAM INFECTIONS RELATED TO THE USE OF NEEDLESS MECHANICAL VALVE CONNECTORS IN LONG-TERM CENTRAL VENOUS CATHETERS | Nélson Domingues | Received |
427-P | A RETROSPECTIVE STUDY OF THE RELATIONSHIP BETWEEN VITAMIN D SUPPLEMENTATION AND THE RISK OF FEBRILE NEUTROPENIA(FN) IN ADULTS WITH HEMATOLOGICAL MALIGNANCIES IN EAST KENT HOSPITALS(EKUFHT) | Salah-Eldin Alhassan | Received |
428-P | INFECTIONS CAUSED BY CARBAPENEMASE PRODUCING KLEBSIELLA PNEUMONIAE IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES | Maria Stamouli | Received |
431-P | ABNORMAL SPLEEN FUNCTION ASSESSED BY THE STUDY OF PITS AND SUBMEMBRANOUS VACUOLES IN ERYTHROCYTES IN PATIENTS WITH SPLENOMEGALY OF DIFFERENT ETIOLOGY | EVARIST FELIU | Received |
432-P | NEUTROPENIC ENTEROCOLITIS AND VANCOMYCIN RESISTANT ENTEROCOCCUS AS PREDISPOSING FACTOR | Elif Gulsum Umit | Received |
433-P | ANAEROBIC BLOODSTREAM INFECTIONS AMONG HAEMATOLOGICAL CANCER PATIENTS: EPIDEMIOLOGY AND OUTCOME. RESULTS OF AN 8-YEAR SURVEILLANCE PROGRAM AT A SINGLE INSTITUTION | Chiara Cattaneo | Received |
434-P | COMPARISON OF THE BD GENEOHMVANR ASSAY TO CULTURE FOR IDENTIFICATION OF VANCOMYCIN-RESISTANT ENTEROCOCCI IN RECTAL AND STOOL SPECIMENS IN PEDIATRIC MALIGNANCY PATIENTS | yaman yntem | Received |
435-P | REASONS FOR TREATMENT SEEKING DELAY IN NEUTROPENIC SEPSIS | Marc Talbot | Received |
436-P | CEFEPIME-INDUCED ENCEPHALOPATHY IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: CLINICAL FEATURES AND RISK FACTORS | Tomotaka Ugai | Received |
438-P | USEFULNESS OF GALACTOMANNAN ASSAY IN BRONCHOALVEOLAR LAVAGE SAMPLES IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES AND RISK OF INVASIVE PULMONARY ASPERGILLOSIS. | Rafael Del Orbe Barreto | Received |
439-P | RISK FACTORS RELATED TO MORTALITY IN HEMATOLOGICAL PATIENTS ADMITTED TO INTENSIVE CARE UNIT (ICU) | Sandra Iraheta | Received |
442-P | DIAGNOSTIC EFFICACY OF GALACTOMANNAN ASSAY AND COMPUTERIZED CHEST TOMOGRAPHY IN INVASIVE ASPERGILLOSIS OF FEBRILE NEUTROPENIC CHILDREN | Gonul Aydogan | Received |
443-P | VESICLES OBSERVED IN LEUCOREDUCED AND NON LEUCOREDUCED CONCENTRATED RED BLOOD CELLS BY MEANS OF ADVANCED MICROSCOPES: POSSIBLE RELATION TO THE STORAGE LESION | Dimosthenis Stamopoulos | Received |
445-P | Alloantibody formation is increased in Sickle Cell Disease patients compared to the general population | Joep Sins | Received |
446-P | THE ROLE OF BLOOD TRANSFUSION IN BETA-THALASSEMIA: AN EX VIVO STUDY OF HEMOSTATIC PARAMETERS | Alice Trinchero | Received |
448-P | TRANSCRIPTIONAL PROFILING OF HUMAN ERYTHROID PROGENITORS FROM G-CSF MOBILIZED AND NONMOBILIZED PERIPHERAL BLOOD | Vladan Cokic | Received |
450-P | MATERNAL AND FETAL OUTCOMES IN PREGNANT PATIENTS WITH SICKLE CELL DISEASE WHO APPLIED PROPHYLACTIC RED BLOOD CELL EXCHANGE PROCEDURE | Ilknur Kozanoglu | Received |
452-P | ANCESTIM VERSUS PLERIXAFOR FOR THE COLLECTION OF PERIPHERAL BLOOD STEM CELLS | Adrian Tempescul | Received |
453-P | BONE MARROW ASPIRATE MORPHOLOGIC, IMMUNOPHENOTYPIC AND CYTOGENETIC EVALUATION IN RELATED DONORS PRIOR TO HEMATOPOIETIC STEM CELL DONATION | Raffaella Milani | Received |
454-P | THE USE OF PREOPERATIVE ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) IN PATIENTS WHO UNDERWENT KNEE OR HIP ARTHROPLASTY | Ghazi Alotaibi | Received |
456-P | FAILURE ON MAINTAINING HAEMOGLOBIN LEVEL AFTER TRANSFUSION IN TRANSFUSION DEPENDENT THALASSEMIA PATIENTS RELATED TO ERYTHROCYTE ALLOANTIBODY AND AUTOANTIBODY PRODUCTION: PROPORTION AND REL | Andree Kurniawan | Received |
457-P | EFFECT OF USING LEUKOSTOP FILTER DURING BLOOD TRANSFUSION ON PULMONARY FUNCTIONS IN PATIENTS WITH THALASSEMIA MAJOR | Iman Ragab | Received |
458-P | PLATELET TRANSFUSIONS IN HAEMATOLOGY PATIENTS | bachra choufi | Received |
459-P | THE EFFECTIVENESS OF PLATELETS TRANSFUSIONS IN PATIENTS WITH DE NOVO ACUTE MYELOID LEUKEMIA (AML) DURING INDUCTION CHEMOTHERAPY (IC). | Bulgan Davaasambuu | Received |
460-P | MEASUREMENT OF IRON CONCENTRATION IN HAIR AS AN INDICATOR OF BODY IRON LOAD | Yasemin Altuner Torun | Received |
461-P | REVIEW AND DESIGN OF A NEW BLOOD BOOKING PROTOCOL FOR EACH SURGERY AND A RESTROSPECTIVE STUDY OF THE DIRECT EXPENSE DECREASE WITH THE NEW PROTOCOL | Angel Pereda Vicandi | Received |
462-P | A CANADIAN TALE OF TWO BLOOD GROUPS | Conal McConville | Received |
466-P | RECOMBINANT HUMAN THROMBOPOIETIN (RHTPO) IN COMBINATION WITH LOW-DOSE RITUXIMAB (LD RTX) IN SEVERE OR REFRACTORY PRIMARY IMMUNE THROMBOCYTOPENIA: A MULTICENTER PROSPECTIVE CLINICAL TRIAL | MING HOU | Received |
470-P | RITUXIMAB VERSUS SPLENECTOMY IN PERSISTENT OR CHRONIC ADULT PRIMARY IMMUNE THROMBOCYTOPENIA: AN ADJUSTED COMPARISON OF MORTALITY AND MORBIDITY | Guillaume Moulis | Received |
471-P | EVALUATION OF THE IMMATURE PLATELET FRACTION IN THE DIAGNOSIS AND PROGNOSIS OF CHILDHOOD IDIOPATHIC THROMBOCYTOPENIC PURPURA | Amira Adly | Received |
472-P | THALIDOMIDE CORRECTS IMPAIRED MESENCHYMAL STEM CELL FUNCTION IN INDUCING TOLEROGENIC DENDRITIC CELLS IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA | JUN PENG | Received |
473-P | DISEASE PROGRESSION, TREATMENT PATTERNS, AND CO-MORBID BURDEN AMONG ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP): UPDATED RESULTS FROM THE UNITED KINGDOM ITP REGISTRY | Dimitri Bennett | Received |
474-P | THROMBOEMBOLIC EVENTS IN PATIENTS WITH ADULT CHRONIC IMMUNE THROMBOCTOPENIA (ITP) TREATED WITH ELTROMBOPAG | shojiro Takagi | Received |
475-P | MANAGEMENT OF ADULT CHRONIC IMMUNE THROMBOCYTOPENIA IN JAPAN: PATIENT AND HEMATOLOGIST PERSPECTIVES | Norio Komatsu | Received |
476-P | D-DIMER LEVELS IN ACUTE IDIOPATHIC AND SECONDARY THROMBOTIC THROMBOCYTOPENIC PURPURA | Andrew Grosset | Received |
477-P | THROMBOCYTOPENIA IN PREGNANCY: OUR EXPERIENCE AT THE NATIONAL MATERNITY HOSPITAL | MATIAS DIAZ | Received |
478-P | MONITORING ANTIPLATELET THERAPY : ACTIVITY OF ADENOSINE DIPHOSPHATE RECEPTOR INHIBITORS IN PATIENTS AFTER PERCUTANEOUS CORONARY INTERVENTION | Marian Fedor | Received |
479-P | ANALYSIS OF RETICULATED PLATELETS IN THE ROUTINE CLINICAL PRACTICE USING THE CELL-DYN SAPPHIRE INSTRUMENT | Hans Wadenvik | Received |
481-P | THE ROLE OF OXIDATIVE STRESS IN CHILDREN WITH ACUTE AND CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA | Erol Erduran | Received |
482-P | PILOT OBSERVATIONAL STUDY OF ROTATIONAL THROMBOELASTOMETRY (ROTEM) TO PREDICT BLEEDING RISK IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES (ATHENA STUDY) | Lise Estcourt | Received |
483-P | AUTOCRINE AMPLIFICATION OF INTEGRIN aIIBb3 ACTIVATION AND PLATELET ADHESIVE RESPONSES BY DEOXYRIBOSE-1-PHOSPHATE | Dina Vara | Received |
484-P | INCREASED CIRCULATING MICROPARTICLES COEXPRESSING ENDOTHELIAL AND PLATELET MARKERS IN ISCHEMIC CEREBRAL STROKE | Ghada Ezzat | Received |
485-P | LOW MOLECULAR WEIGHT HEPARIN (LMWH) FOR PRIMARY THROMBOPROPHYLAXIS OF AMBULATORY PATIENTS WITH SOLID CANCER SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS | Anat Gafter-Gvili | Received |
486-P | PLATELET COUNTS DECREASE WITH INCREASING LUPUS-LIKE ANTICOAGULANT RATIOS, IRRESPECTIVE OF ANTIPHOSPHOLIPID SYNDROME CRITERIA | Marta Pereira | Received |
487-P | REDOX-DEPENDENT ANGIOGENESIS BY NUCLEOSIDE DERIVATIVES OF DEOXYRIBOSE-1-PHOSPHATE | Dina Vara | Received |
488-P | THE JAK2 V617F MUTATION IN PATIENTS WITH CEREBRAL VENOUS THROMBOSIS IS ASSOCIATED WITH AN INCREASED RISK OF RECURRENCE | Valerio De Stefano | Received |
490-P | ADVANTAGES AND DISADVANTAGES OF INCORPORATING C-REACTIVE PROTEIN LEVELS, AGE AND D-DIMER LEVELS IN DIAGNOSING PULMONARY EMBOLISM | Meindert Crop | Received |
491-P | EVALUATING ACQUIRED DISORDERS OF PROTEIN C SYSTEM IN PATIENTS ON VITAMIN K ANTAGONISTS TREATMENT BY THE CALIBRATED AUTOMATED THROMBOGRAM | Veronika Shmeleva | Received |
493-P | THE ROLE OF ANTICOAGULANT THERAPIES ON COAGULOPATHY (DISSEMINATED INTRAVASCULAR COAGULATION) IN PATIENTS WITH HEMOLYTICUREMIC SYNDROME AFTER INFECTION WITH ENTEROHEMORRHAGIC ESCHERICHIA COLI O111. | Jun Murakami | Received |
494-P | UNEXPECTED FATAL PULMONARY EMBOLISM FOUND AT FORENSIC AUTOPSIES | Mariana Villegas Scivetti | Received |
496-P | ANTITHROMBOTIC PROPHYLAXIS IN PREGNANT WOMEN WITH ANTITHROMBIN CONGENITAL DEFICIENCY IS EFFECTIVE IN PREVENTING ADVERSE OUTCOMES | Valerio De Stefano | Received |
497-P | HIGH PREVALENCE OF PROTEIN S DEFICIENCY IN THAI POPULATION | Ponlapat Rojnuckarin | Received |
498-P | MANAGEMENT OF EXCESSIVE ANTICOAGULATION IN PATIENTS TREATED WITH ACENOCOUMAROL, A VITAMIN K ANTAGONIST. | Jesus Cesar | Received |
499-P | GENETIC POLYMORPHISMS RELATED TO HEMOSTASIS AND THEIR ASSOCIATION WITH PRIMARY RECURRENT PREGNANCY LOSS | Elvira Guerra-Shinohara | Received |
500-P | HIGH ON-TREATMENT PLATELET REACTIVITY: NOT AN ISOLATED PROBLEM | Martin Jakl | Received |
501-P | EVALUATION OF PIVKA-II AS A PREDICTOR MARKER FOR PORTAL VEIN THROMBOSIS IN HEPATOCELLULAR CARCINOMA PATIENTS | Maryse Ayoub | Received |
503-P | PERIPHERALLY INSERTED CENTRAL CATHETERS (PICCS) CAN BE SUCCESSFULLY UTILIZED IN HAEMATOLOGICAL PATIENTS RECEIVING INTENSIVE CHEMOTHERAPY OR ALLOGENEIC/AUTOLOGOUS STEM CELL TRANSPLANTATION | Alessandra Malato | Received |
504-P | PICC INSERTION AND MANAGEMENT IN HEMATOLOGY PATIENTS: 5 YEARS PROSPECTIVE STUDY THE CAGLIARIS DEPARTMENT OF HAEMATOLOGY | Daniele Derudas | Received |
505-P | A NEW SCORE TO DETERMINE THE PROBABILITY OF FINDING AN HLA IDENTICAL UNRELATED DONOR: A VALIDATED EFFICIENT TIME AND COST SAVING METHOD | Mauricette Michallet | Received |
506-P | ESTIMATES OF BURDEN OF DISEASE ASSOCIATED WITH MANAGEMENT OF ACUTE MYELOID LEUKEMIA IN UK AND US | Izabela Kucmin | Received |
511-P | THE IMPACT OF UNRESTRICTED FUNDING ON HAEMATO-ONCOLOGY TREATMENT CHOICE | Tony Todd | Received |
512-P | PATIENT SAFETY AND CLINICAL EFFICIENCY GAINS FOLLOWING IMPLEMENTATION OF AN INTEGRATED HEALTH INFORMATION SYSTEM IN EAST LONDON. | Ciara Freeman | Received |
513-P | PHARMACOLOGICAL DRUG EXPENDITURE OF FIRST-LINE INDOLENT NON-HODGKIN LYMPHOMAS IN SPAIN | Juan Manuel Collar | Received |
514-P | A SYSTEMATIC REVIEW OF ECONOMIC ANALYSES, UTILITY, RESOURCE USE, AND COST ESTIMATES OF FIRST-LINE TREATMENTS FOR CHRONIC LYMPHOCYTIC LEUKEMIA | Amin Haiderali | Received |
515-P | A COST-BENEFIT ASSESSMENT OF TREATMENT (TX) FOR NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS: AN EFFICIENCY FRONTIER APPROACH | Shien Guo | Received |
518-P | A CALL FOR A STANDARDISED MEASUREMENT OF HAEMOGLOBIN IN THE REPUBLIC OF IRELAND | Jennifer O Sullivan | Received |
519-P | DEMAND MANAGEMENT IN A UNIVERSITY LABORATORY IN THE WEST OF IRELAND; THE FINANCIAL BENEFIT OF DISTRIBUTION OF LOCAL GUIDELINES FOR VITAMIN B12 TESTING. | Aoibheann Ni Chonfhaola | Received |
617-P | A COHORT STUDY OF POST-RELAPSE/RESISTANCE SURVIVAL IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA | TAMARA INTERMESOLI | Received |
618-P | A SEQUENTIAL USE OF TKI, CHEMOTHERAPY AND TRANSPLANT IS ASSOCIATED WITH HIGH COMPLETE REMISSION RATES, DISEASE-FREE AND OVERALL SURVIVAL IN ADULT PH ALL. RESULTS OF THE GIMEMA 0904 PROTOCOL | Sabina Chiaretti | Received |
619-P | Comorbidity impacts on complete remission rate in elderly patients with acute lymphoblastic leukemia | Colombe Saillard | Received |
620-P | CLL PATIENTS CARRYING 13q DELETION SHOW CLINICAL HETEROGENEITY ACCORDING TO IGHV MUTATIONAL STATUS AND CD38 EXPRESSION | Andrea Visentin | Received |
621-P | COMPARABLE OUTCOME OF HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION AS POST-REMISSION THERAPY IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: INTERIM ANALYSIS OF PROSPECTIVE STUDY | Dae-Young Kim | Received |
623-P | MRD LEVEL ANALYSIS IN ADULT ALL PATIENTS. ANALYSIS OF THE CZECH LEUKEMIA STUDY GROUP FOR LIFE (CELL) | Cyril álek | Received |
624-P | FLUDARABINE, ARA-C AND LIPOSOMAL DAUNORUBICIN (FLAD) PLUS HEMOPOIETIC STEM CELL TRANSPLANT (HSCT) AS SALVAGE THERAPY IN PATIENTS WITH RELAPSED-REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA. | Marino Clavio | Received |
626-P | CLINICAL OUTCOME OF T- ACUTE LYMPHOBLASTIC LEUKEMIA/ LYMPHOMA (T-ALL/T-LBL) : THE BOLOGNA EXPERIENCE | mariachiara abbenante | Received |
627-P | ENCOURAGING SURVIVAL IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA - RESULTS OF RUSSIAN ACUTE LYMPHOBLASTIC LEUKEMIA (RALL) STUDY GROUP | Elena Parovichnikova | Received |
629-P | FOUR YEARS EXPERIENCE WITH HYPER-CVAD TREATMENT OF ADULT T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA IN SWEDEN. POPULATION-BASED DATA. | Piotr Kozlowski | Received |
631-P | ADULT MIXED-PHENOTYPE ACUTE LEUKEMIA ACCORDING TO THE WHO 2008 CLASSIFICATION A SINGLE CENTER EXPERIENCE | Claudia Moreira | Received |
632-P | INTEGRATING ALTERNATIVE DONORS ALLOWS BEST OUTCOMES IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN HIGH RISK ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: A SINGLE CENTRE STUDY | Barbara Forno | Received |
633-P | OBESITY, INSULIN RESISTANCE AND ADIPOKINES IN SURVIVORS OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA. | Trkiz Grsel | Received |
634-P | ZAP70 GENE EXPRESSION MAY BE A PROGNOSTIC FACTOR FOR ADULT ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS | Bing Xu | Received |
638-P | EFFECTS OF PROPHYLACTIC CRANIAL RADIOTHERAPY ON GROWTH HORMONE SECRETION OF CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA | Gonul Aydogan | Received |
639-P | THE IMPACT OF RISK STRATIFICATION BY EARLY BONE-MARROW RESPONSE AND FCM-MRD IN CHILDHOOD LYMPHOBLASTIC LEUKAEMIA (A SINGLE INSTITUTION EXPERIENCE IN AZIZA OTHMANA HOSPITAL, TUNIS, TUNISIA). | BEN ABDENNEBI Yosr | Received |
641-P | IDENTIFICATION OF NOVEL GENETIC ALTERATIONS BY WHOLE-TRANSCRIPTOME SEQUENCING IN INFANTS WITH CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIA | Marco Togni | Received |
643-P | ALTERED GENES DOWNSTREAM OF MYCN IN ACUTE MYELOID LEUKEMIA IN ZEBRAFISH BY RETINOIC ACID AND VALPROIC ACID | Li-Jing SHEN | Received |
645-P | EXPRESSION, REGULATION AND FUNCTIONAL ROLES OF THE CHEMOKINE RECEPTOR CXCR7 IN ACUTE MYELOID LEUKAEMIA CELLS | Deog-Yeon Jo | Received |
646-P | INTERLEUKIN-3 RECEPTOR ALPHA CHAIN (CD123) AS A MARKER FOR LEUKEMIC STEM CELLS IN ACUTE MYELOID LEUKEMIA AND ITS RELATION TO DISEASE PROGRESSION | Hanan Alwakeel | Received |
647-P | EFFECTS OF B-MYB ABERRANT EXPRESSION ON HEMATOPOIETIC PROGENITOR CELL GROWTH AND DETECTION OF GENETIC VARIATIONS THAT MAY MODIFY ITS PROTEIN FUNCTION | SANDRA DOLZ GIMÉNEZ | Received |
648-P | MUTATIONS IN RUNX1 AND NPM1 COMBINED WITH IMBALANCES OF CHROMOSOME 21 ARE PREDICTIVE FOR PROGRESSION OF AML | Katya Gancheva | Received |
649-P | PROGNOSTIC VALUE OF B-MYB AND ITS REGULATION BY MIRNAS IN ACUTE MYELOID LEUKEMIA | Marta Llop García | Received |
651-P | CLINICAL AND HEMATOLOGICAL FEATURES OF ACUTE MYELOID LEUKEMIA WITH REARRANGEMENTS OF EVI1 OR PRDM16 | marion eveillard | Received |
653-P | IMPACT OF THE E3 UBIQUITIN LIGASE TRAF2 ON TNF-?-INDUCED APOPTOSIS IN A CELL MODEL OF FLT3-ITD-POSITIVE AML | Sebastian Scholl | Received |
654-P | PLUMBAGIN ENHANCED TRAIL-INDUCED APOPTOSIS OF KASUMI-1 CELLS IN NOD / SCID MICE | Li-Gen Liu | Received |
658-P | IMPLICATIONS OF MIR-10 IN CHEMOTHERAPY RESPONSE OF NPM1 MUTATED AML | ramiro garzon | Received |
660-P | SYNERGISTIC EFFECTS OF HSP70 AND HSP90 INHIBITORS IN PRIMARY HUMAN ACUTE MYELOID LEUKEMIA CELLS | Hkon Reikvam | Received |
662-P | IMPROVEMENT, BUT STILL POOR PROGNOSIS FOR ESTONIAN PATIENTS COMPARED TO A WELL-DEFINED REGION OF WESTERN SWEDEN, A POPULATION BASED STUDY OF ACUTE DE NOVO LEUKEMIA PATIENTS AGED 16-64 YEARS | Erik Hulegrdh | Received |
663-P | PROGNOSTIC IMPACT OF NPM1, IDH1/2 AND DNAH11 GENE MUTATIONS ON NORMAL KARYOTYPE ACUTE MYELOID LEUKEMIA PATIENTS NOT HARBORING FLT3/ITD MUTATION | Yeo-Kyeoung Kim | Received |
664-P | ROLE OF ALLOGRAFTING IN HIGH RISK ACUTE MYELOID LEUKEMIA | Benedetto Bruno | Received |
667-P | SYSTEMIC VERSUS LOCALIZED THERAPEUTIC APPROACH FOR ISOLATED MYELOID SARCOMA: META-ANALYSIS OF INDIVIDUAL PATIENT DATA | Darko Antic | Received |
669-P | LOW MDR1 AND BAALC EXPRESSION IDENTIFIES A NEW SUBGROUP OF ADULT CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIA WITH A FAVORABLE OUTCOME | Xutao Guo | Received |
670-P | THE SURFACE MOLECULAR SIGNATURE OF LEUKEMIC CELLS WAS ASSOCIATED WITH NPM1 AND FLT3-ITD MUTATIONS IN ACUTE MYELOID LEUKEMIA | SuJun Gao | Received |
671-P | IMPACT OF DAY 14 BONE MARROW EXAMINATION ON RE-INDUCTION DECISION AND PREDICTION OF COMPLETE RESPONSE IN ACUTE MYELOGENOUS LEUKEMIA (AML) | Aamer Aleem | Received |
672-P | ADVERSE PROGNOSTIC SIGNIFICANCE OF FLT3 MUTATIONS IN ACUTE PROMYELOCYTIC LEUKEMIA | mirjana mitrovic | Received |
675-P | PERIPHERAL BLOOD BLASTS ON DAY 7 OF INITIAL INDUCTION THERAPY PREDICT RESPONSE TO CHEMOTHERAPY AND SURVIVAL IN PATIENTS WITH ACUTE MYELOID LEUKEMIA | SuJun Gao | Received |
676-P | PROGNOSTIC VALUE OF TH17 CELLS IN ACUTE LEUKEMIA | Manal Salah Eldin | Received |
677-P | STUDIES ON BCR AND TLR SIGNALLING IN AGGRESSIVE CLL- THE CASE OF STEREOTYPED SUBSET 1 | Ann-Charlotte Bergh | Received |
678-P | THE PHOSPHO-PROTEOMIC PROFILE OF CD49D-EXPRESSING CIRCULATING CHRONIC LYMPHOCYTIC LEUKEMIA CELLS IS CONSISTENT WITH CONSTITUTIVE RECEPTORIAL ENGAGEMENT BY BLOOD-BORNE LIGANDS | Dania Benedetti | Received |
682-P | SINGLE CELL NETWORK PROFILING (SCNP) ANALYSIS REVEALS DYSFUNCTIONAL SIGNALING WITHIN THE TH17 AXIS IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) | Michelle Atallah | Received |
684-P | EXPRESSION OF ZAP-70 IN CLL ACTIVATES NF-KB SIGNALING | Valerie Pede | Received |
685-P | THE PRO-APOPTOTIC MIR-132212/SIRT1/TP53 AXIS IS ACTIVATED UPON B-CELL RECEPTOR TRIGGERING IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS | Riccardo Bomben | Received |
686-P | HETEROGENEOUS FUNCTIONAL EFFECTS OF CONCOMITANT B CELL RECEPTOR AND TOLL-LIKE RECEPTOR STIMULATION IN CLL WITH MUTATED VERSUS UNMUTATED IMMUNOGLOBULIN GENES | Stavroula Ntoufa | Received |
687-P | IGG-SWITCHED CLL HAS A DISTINCT IMMUNOGENETIC SIGNATURE FROM THE COMMON MD VARIANT: ONTOGENETIC IMPLICATIONS | Anna Vardi | Received |
689-P | ABERRANT EXPRESSION OF PD-1 IN CHRONIC LYMPHOCYTIC LEUKEMIA IS INDEPENDENT FROM BCR SINGLING AND PDCD1 GENE POLYMORPHISM | Maciej Grzywnowicz | Received |
695-P | A NEW ONCOGENIC ROLE OF BCR/ABL-OOF IN CHRONIC MYELOID LEUKAEMIA PATHOGENESIS | Cristina Panuzzo | Received |
697-P | MICROVESICLES TRANSCRIPTOME REFLECTS PHYSIOLOGICAL CONDITIONS OF LEUKEMIC PARENTAL CELLS | Gloria Milani | Received |
698-P | THE REFERENCE STANDARD FOR BCR-ABL TRANSCRIPT MONITORING IS IMPORTANT TO DEFINE CMR IN CML PATIENTS AND TO TEST THE RQ-PCR METHOD PERFORMANCES | Rodica TALMACI | Received |
700-P | IDENTIFICATION AND FOLLOW-UP OF TWO NEW RARE E8A2 BCR-ABL FUSION GENES | Sarah Huet | Received |
702-P | EVALUATION OF TOB1 GENE EXPRESSION IN CML PATIENTS AND BLOOD DONOR AND THE EFFECT OF GENE SILENCING IN BCR-ABL CELL LINE | CINTIA MASCARENHAS | Received |
705-P | PATTERNS OF ABL KD MUTATION IN ASIAN PATIENTS WITH IMATINIB-RESISTANT CHRONIC PHASE CHRONIC MYELOID LEUKEMIA | Hawk Kim | Received |
706-P | COMPARISON OF NON AUTOMATED BCR-ABL1 RT-QPCR WITH THE XPERT BCR-ABL MONITOR TM ASSAY | Stephanie Dulucq | Received |
711-P | LONG-TERM SURVIVAL OUTCOME AND PROGNOSIS IN 2277 PATIENTS WITH CHRONIC MYELOID LEUKAEMIA ALLOCATED TO FIRST-LINE IMATINIB TREATMENT NEW RESULTS FROM THE EUTOS IN-STUDY REGISTRY | Markus Pfirrmann | Received |
713-P | DEFINING LOW AND UNDETECTABLE LEVELS OF DISEASE IN CHRONIC MYELOID LEUKAEMIA: PROGRESS TOWARDS STANDARDISATION IN EUROPE | Helen White | Received |
714-P | CLINICAL SIGNIFICANCE OF EARLY MOLECULAR RESPONSES (BCR-ABL1 =10 AT 3 MONTHS AND =1 6 MONTHS) AS A PREDICTOR FOR LONG-TERM OUTCOMES IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH IMATINIB | Sung-Eun Lee | Received |
716-P | HEPATITIS B VIRUS REACTIVATION IN CHRONIC MYELOID LEUKEMIA TREATED WITH VARIOUS TYROSINE KINASE INHIBITORS: A MULTICENTER RETROSPECTIVE STUDY | Sung-Hyun Kim | Received |
717-P | EARLY AND DEEP RESPONSES TO IMATINIB PREDICT NOT ONLY COMPLETE MOLECULAR RESPONSE BUT ALSO THE PROBABILITY FOR MAINTAINING THE RESPONSE. | Valentín García-Gutiérrez | Received |
720-P | IN CML PATIENTS TREATED FRONTLINE WITH IMATINIB, WITH A BCR-ABL RATIO HIGHER THAN 10 AT 3 MONTHS, THE CHANGE TO A 2ND GTKI IS ASSOCIATED WITH IMPROVEMENT OF CYTOGENETIC RESPONSE, BUT NOT WITH MMR | LUIS FELIPE CASADO MONTERO | Received |
721-P | CLINICAL AND BIOLOGICAL FEATURES OF BLAST CRISIS (BC) IN PATIENTS WITH PH CHRONIC MYELOID LEUKEMIA (CML) IN THE TKIS ERA: EXPERIENCES IN CLINICAL PRACTICE | Antonella Russo Rossi | Received |
722-P | REVERSIBLE LYMPH NODE FOLLICULAR HYPERPLASIA ASSOCIATED WITH DASATINIB TREATMENT FOR CHRONIC MYELOID LEUKAEMIA IN CHRONIC PHASE | Clémence Roux | Received |
723-P | Descriptive study of CML patients in major molecular response (MMR) with an evaluation of clinical and therapeutic characteristics leading to the conversion into a complete molecular response (CMR) | Mauricette Michallet | Received |
726-P | EUTOS CML PROGNOSTIC SCORING SYSTEM PREDICTS ELN-BASED EVENT-FREE SURVIVAL BETTER THAN EURO/HASFORD AND SOKAL SYSTEMS IN CHRONIC PHASE CML PATIENTS RECEIVING FRONTLINE IMATINIB MESYLATE | Nilgun Sayinalp | Received |
728-P | BONE MARROW IMAGING OF HUMERAL AND FEMORAL MARROW BY MULTI-DETECTOR COMPUTED TOMOGRAPHY IN PATIENTS WITH APLASTIC ANEMIA AND HYPOPLASTIC MDS | Tomotaka Ugai | Received |
730-P | BONE MARROW SCREENING FOR MYELODYSPLASIA-RELATED CHANGES AND ABERRANT LYMPHOID POPULATIONS USING ONE TUBE, FOURTEEN ANTIBODY-TEN COLOR FLOW CYTOMETRY PANEL | Anna Porwit | Received |
731-P | PLATELET COUNT AND TRANSFUSION-DEPENDENCY AFFECT OVERALL SURVIVAL IN PATIENTS WITH REFRACTORY ANEMIA WITH RING SIDEROBLASTS AND THROMBOCYTOSIS (RARS-T) | Gregory Kaufman | Received |
732-P | A PROSPECTIVE PHASE II STUDY OF ATG-CYCLOSPORINE A FOR ADULT SEVERE APLASTIC ANEMIA: MEDIAN 8-YEAR FOLLOW-UP DATA | Hawk Kim | Received |
733-P | IMPACT OF THE PROLIFERATION INDEX OF SPECIFIC BONE MARROW CELL COMPARTMENTS FROM MYELODYSPLASTIC SYNDROMES IN THE MONITORIZATION OF THE DISEASE: A PILOT STUDY | Sergio Matarraz | Received |
734-P | BENEFITS OF THE USE OF AZACITDINE IN PATIENTS WITH AML REFRACTORY OR RELAPSED AFTER INTENSIVE CHEMOTHERAPY | Claudio Cerchione | Received |
736-P | LONG DURATION OF RESPONSE TO AZACITIDINE IN MYELODYSPLASTIC SYNDROMES. MULTICENTER RETROSPECTIVE STUDY OF 36 PATIENTS | Carlo Finelli | Received |
737-P | PROLONGED LOW-DOSE AZACITIDINE SCHEDULE IN HIGH-RISK MDS PATIENTS: LONG TERM EFFICACY AND RELATIONSHIP WITH MOLECULAR RESPONSE | cristina clissa | Received |
739-P | REAL WORLD USE OF AZACITIDINE IN ELDERLY PATIENTS WITH MDS/AML THE SCOTTISH EXPERIENCE | Kirstin Lund | Received |
740-P | MODELLING THE LONG-TERM SURVIVAL OF PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS) DEL (5Q) TREATED WITH LENALIDOMIDE | Dawn Lee | Received |
741-P | ANALYSIS OF RESPONSE TO ERYTHROPOYESIS STIMULATING AGENTS (ESAS) IN 114 MYELODYSPLASTIC SYNDROME (MDS) PATIENTS FROM REGISTRO CAMPANO DELLE MIELODISPLASIE | Claudio Cerchione | Received |
743-P | RISK SCORING SYSTEM USING IPSS-R, LDH AND PERFORMANCE STATUS TO PREDICT THE OUTCOMES OF PATIENTS WITH LOWER RISK MYELODYSPLASTIC SYNDROME TREATED WITH HYPOMETHYLATING AGENTS | Sang Kyun Sohn | Received |
744-P | PAROXYSMAL NOCTURNAL HEMOGLOBINURIA CLONE: DIAGNOSTIC AND CLASSIFICATION OF 103 BRAZILIAN PATIENTS | ANA PAULA AZAMBUJA | Received |
745-P | ERYTHROPOIETIC ASPECTS IN MDS PATIENTS RESPONDERS TO ESAS TREATMENT | Claudio Cerchione | Received |
746-P | COMPARISON OF IPSS AND R-IPSS IN A SINGLE UNIT PATIENT COHORT | Francesca Pierdomenico | Received |
747-P | DOES REVISED INTERNATIONAL PROGNOSTIC SCORING SYSTEM (IPSS-R) HAVE ANY IMPACT ON CLINICAL OUTCOMES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES TREATED WITH HYPOMETHYLATING AGENTS? | Zhenwei Teo | Received |
749-P | NEW STRATEGIES OF ANALYSIS WITH FLOW CYTOMETRY FOR THE DIAGNOSIS OF MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA | Paola Beneit | Received |
750-P | FREQUENT MUTATION OF THE MYD88 GENE IN MACROGLOBULINEMIA | Naoki Mori | Received |
751-P | THE ROLE OF FLT3-LIGAND IN THE PROGRESSION OF MULTIPLE MYELOMA; FLT3-LIGAND RELEASED FROM BONE MARROW STROMAL CELLS ACTIVATED PI3K/AKT PATHWAY AND WNT SIGNALING | Sung-Soo Yoon | Received |
752-P | CIRCULATING MICRORNA AS POTENTIAL BIOMARKERS OF MGUS AND MM | Lenka Kubiczkova | Received |
754-P | DEF124B, A MEMBER OF THE ?-DEFENSINS, IS DOWNREGULATED IN DIFFERENTIATING OSTEOBLASTS BY EXPOSURE TO IMIDS AND MAY MEDIATE THE SUPPRESSIVE EFFECT OF THESE AGENTS ON OSTEOGENESIS | Heinz Ludwig | Received |
755-P | IDENTIFICATION AND CHARACTERISATION OF THE ROLE OF SAMSN1 IN MYELOMA | Jacqueline Noll | Received |
757-P | NEUTROPHILS ARE IMPAIRED IN MULTIPLE MYELOMA BUT NOT IN MGUS | ALESSANDRA ROMANO | Received |
758-P | IDENTIFICATION OF INSULIN LIKE GROWTH FACTOR BINDING PROTEIN 7 (IGFBP7) AS TUMOR SUPPRESSOR IN MULTIPLE MYELOMA LINKED TO THE PRESENCE OF OSTEOLYTIC LESIONS AND OVERALL SURVIVAL | Heinz Ludwig | Received |
759-P | HIGH RISK CYTOGENETIC ABNORMALITIES AND PLASMA CELLS PHENOTYPE INDUCE SIGNIFICANT ALTERATIONS IN BONE MARROW B-CELL COMPARTMENTS IN MONOCLONAL GAMMOPATHIES | Sofia Ramos | Received |
760-P | ANGIOPOIETIN-2 AND MACROPHAGE INFLAMMATORY PROTEIN-1 ALPHA HAVE DUAL EFFECT ON BONE INVOLVEMENT AND ANGIOGENESIS IN MULTIPLE MYELOMA | George Tsirakis | Received |
761-P | GENE EXPRESSION OF BONE MODULATORS IN WHOLE BONE MARROW BIOPSIES IN CORRELATION TO DYNAMIC BONE MARKERS IN MULTIPLE MYELOMA BONE DISEASE | Ida Bruun Kristensen | Received |
762-P | P15 AND DAPK METHYLATION IN MULTIPLE MYELOMA AND MGUS: COMPARISON BETWEEN BONE MARROW AND PERIPHERAL BLOOD | Catarina Geraldes | Received |
768-P | SAFETY AND EFFICACY OF POMALIDOMIDE WITH OR WITHOUT LOW-DOSE DEXAMETHASONE IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA: LONG-TERM FOLLOW-UP OF PATIENTS ENROLLED IN THE MM-002 PHASE 2 TRIAL | Paul Richardson | Received |
769-P | CONSOLIDATION WITH HD- MELPHALAN AND AUTOTRANSPLANT (ASCT) AFTER SECOND-LINE TREATMENT INCREASES RESPONSE RATE AND PROGRESSION-FREE SURVIVAL IN MYELOMA PATIENTS RELAPSED AFTER FIRST-LINE ASCT | Claudia Crippa | Received |
770-P | TOTAL THERAPY 3 (TT3)-BASED TREATMENT FOR MULTIPLE MYELOMA AN EXTENDED SINGLE CENTER EXPERIENCE | Eli muchtar | Received |
772-P | MM-008: A PHASE 1 TRIAL EVALUATING PHARMACOKINETICS AND TOLERABILITY OF POMALIDOMIDE LOW-DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WITH RENAL IMPAIRMENT | Jeffrey Matous | Received |
773-P | CAUSES OF DEATH 30 AND 180 DAYS AFTER DIAGNOSIS IN NON-HDT TREATED DANISH MULTIPLE MYELOMA PATIENTS: A STUDY FROM THE DANISH MYELOMA STUDY GROUP | Morten Orebo Holmstrm | Received |
774-P | PRELIMINARY RESULTS OF A PHASE I/II STUDY OF CARFILZOMIB, LENALIDOMIDE, VORINOSTAT AND DEXAMETHASONE (QUAD) IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (MM) | Elizabeth Bilotti | Received |
777-P | THE UK LENALIDOMIDE TREATMENT CONTINUATION SCHEME: TRENDS OF LONG-TERM TREATMENT IN A CLINICAL SETTING | Cathy Williams | Received |
778-P | THE EFFICACY AND SAFETY OF POMALIDOMIDE WITH OR WITHOUT LOW-DOSE DEXAMETHASONE IS NOT IMPACTED BY AGE IN PATIENTS WITH ADVANCED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: MM-002 SUBGROUP ANALYSIS | Sundar Jagannath | Received |
779-P | PROMISING ROLES OF AMIFOSTINE AS PROPHYLACTIC AGENTS AGAINST BORTEZOMIB-INDUCED PERIPHERAL NEUROPATHY | Meiyun Fang | Received |
780-P | MP VS MPT IN FIRST TO FOURTH LINE OF TREATMENT IN MULTIPLE MYELOMA PATIENTS | Johan Lund | Received |
781-P | CAN NOVEL AGENTS OVERCOME THE NEGATIVE PROGNOSTIC IMPACT OF RENAL IMPAIRMENT IN MULTIPLE MYELOMA? - A POPULATION BASED STUDY INCLUDING 1538 PATIENTS | Katarina Uttervall | Received |
784-P | SESTAMIBI TECHNETIUM-99M BONE MARROW SCAN IS ABLE TO PREDICT OVERALL DISEASE OUTCOME AND MORTALITY COMPARED TO WHOLE BODY MAGNETIC RESONANCE IMAGING IN MULTIPLE MYELOMA | Alhossain Khalafallah | Received |
788-P | ADVERSE EVENTS AND MANAGEMENT IN MM-003, A PHASE 3 STUDY OF POMALIDOMIDE LOW-DOSE DEXAMETHASONE (POM LODEX) VS. HIGH-DOSE DEXAMETHASONE (HIDEX) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) | Michel Delforge | Received |
789-P | VTD CONSOLIDATION, WITHOUT BISPHOSPHONATES, REDUCES BONE RESORPTION AND IS ASSOCIATED WITH A VERY LOW INCIDENCE OF SKELETAL-RELATED EVENTS IN PATIENTS WITH MULTIPLE MYELOMA POST-ASCT | Dimitrios Christoulas | Received |
790-P | IMPACT OF RENAL IMPAIRMENT ON THE EFFICACY AND SAFETY OF MELPHALAN-PREDNISONE-LENALIDOMIDE (LEN) INDUCTION FOLLOWED BY LEN MAINTENANCE IN NEWLY DIAGNOSED MULTIPLE MYELOMA: MM-015 POST-HOC ANALYSIS | Michele Cavo | Received |
791-P | TREATMENT WITH BORTEZOMIB-BASED REGIMENS IMPROVES OVERALL RESPONSE AND PREDICTS FOR SURVIVAL IN PATIENTS WITH PRIMARY OR SECONDARY PLASMA CELL LEUKEMIA: ANALYSIS OF THE GREEK MYELOMA STUDY GROUP | Eirini Katodritou | Received |
792-P | EUROPEAN POST-APPROVAL SAFETY STUDY (PASS) OF RELAPSED/ REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED DATA ON SAFETY AND SPM INCIDENCE IN PATIENTS TREATED WITH LENALIDOMIDE, THALIDOMIDE, AND BORTEZOMIB | Michele Cavo | Received |
794-P | CIRCULATING SOLUBLE RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B LIGAND (SRANKL) AND C-C MOTIF LIGAND-3 (CCL-3) LEVELS CORRELATE WITH SURVIVAL IN PATIENTS WITH WALDENSTROMS MACROGLOBULINEMIA | Dimitrios Christoulas | Received |
795-P | RESULTS OF THE DUTCH COMMUNITY BASED TRIAL VALEO WITH BORTEZOMIB TREATMENT IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS | Richard Milek | Received |
797-P | HIGH RISK CYTOGENETICS, ELEVATED LDH AND ISS-3 IDENTIFY A SUBGROUP OF MYELOMA PATIENTS WITH VERY POOR PROGNOSIS | Efstathios Kastritis | Received |
798-P | BONE BIOMARKERS ARE USEFUL IN MONITORING MYELOMA BONE DISEASE AND AS EARLY PREDICTOR FOR RELAPSE DISEASE IN MULTIPLE MYELOMA | Kay Reen Ting | Received |
799-P | EX VIVO PHARMACOLOGICAL EVALUATION OF 19 DRUGS IN AN AVERAGE OF 50 MULTIPLE MYELOMA PATIENTS USING WHOLE BONE MARROW SAMPLES ANALYZED BY AUTOMATED FLOW CYTOMETRY | Belén Liébana | Received |
800-P | THE IMPACT OF 8 GY ONE FRACTION RADIOTHERAPY ON PAIN RELIEF AND RECALCIFICATION IN MULTIPLE MYELOMA PATIENTS WITH PAINFUL BONE DESTRUCTIONS. | Milda Rudzianskiene | Received |
801-P | RESULTS OF LENALIDOMIDE TREATMENT FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA IN A REAL WORLD SETTING: FEASIBILITY AND FACTORS CONTRIBUTING TO LONG TREATMENT DURATION | Gunter Derigs | Received |
802-P | THE PRESENCE OF IMMUNOPHENOTYPIC ALTERATIONS IN BONE MARROW CELLS OTHER THAN PLASMA CELLS FROM MULTIPLE MYELOMA PATIENTS PREDICTS FOR MYELODYSPLASIA-ASSOCIATED CYTOGENETIC ABNORMALITIES | Sergio Matarraz | Received |
804-P | FLOW CYTOMETRIC ANALYSIS AND MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA: A COMPARISON BETWEEN FLOW CYTOMETRIC IMMUNOPHENOTYPING AND CYCLOSCOPE-MG. | GIACOMA DE TULLIO | Received |
805-P | NUMBER OF ADVERSE CYTOGENETIC LESIONS DETECTED BY FISH IS ASSOCIATED WITH PROGNOSIS IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH THALIDOMIDE-BASED REGIMENS | Norbert Grzasko | Received |
806-P | EVALUATION OF TNF SUPERFAMILY MOLECULES IN MULTIPLE MYELOMA PATIENTS: CORRELATION WITH BIOLOGICAL AND CLINICAL FEATURES. | Bolkun Lukasz | Received |
807-P | TOXICITY PROFILE DURING TREATMENT WITH BENDAMUSTINE-BORTEZOMIB-DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA | Heinz Ludwig | Received |
808-P | VALUE OF WHOLE-BODY DIFFUSION-WEIGHTED MAGNETIC RESONANCE IMAGING IN THE STUDY OF MONOCLONAL GAMMOPATHIES AND CORRELATION WITH BONE-RELATED CYTOKINES | RAFAEL MARTOS MARTINEZ | Received |
809-P | THE COMBINATION OF BORTEZOMIB AND DEXAMETHASONE (VD) ALONG WITH ZOLEDRONIC ACID INCREASES BONE MINERAL DENSITY (BMD) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: RESULTS OF A PHASE II STUDY | Dimitrios Christoulas | Received |
810-P | LONG TERM THERAPY WITH LENALIDOMIDE DOES NOT SIGNIFICANTLY AFFECT THE CELLULAR COMPOSITION OF THE BONE MARROW | Annamaria Brioli | Received |
811-P | A RETROSPECTIVE REVIEW OF THE INCIDENCE OF CONTRAST INDUCED NEPHROPATHY IN THE MYELOMA SETTING | Maeve Crowley | Received |
812-P | EFFECTS OF BORTEZOMIB ON RENAL IMPAIRMENT MULTIPLE MYELOMA PATIENTS | wenming chen | Received |
813-P | THE MM-021 CHINA REGISTRATION TRIAL: A PHASE 2 STUDY OF LENALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE IN CHINESE RELAPSED/REFRACTORY MYELOMA PATIENTS | Jian Hou | Received |
816-P | LONG TERM FOLLOW-UP OF TREATMENT WITH IMATINIB IN EOSINOPHILIA-ASSOCIATED MYELOID/LYMPHOID NEOPLASMS WITH PDGFR REARRANGEMENTS IN ADVANCED PHASE | Georgia Metzgeroth | Received |
819-P | HOW MANY CHILDREN WITH THROMBOCYTOSIS OF UNDEFINED ORIGIN HAVE A MYELOPROLIFERATIVE NEOPLASM? | Maria Luigia Randi | Received |
821-P | CLINICAL FEATURES OF PATIENTS WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS COMPLICATED BY PORTAL HYPERTENSION | Matthew Yan | Received |
822-P | EOSINOPHILIA IN ROUTINE BLOOD SAMPLES AND THE SUBSEQUENT RISK OF HEMATOLOGICAL MALIGNANCIES AND DEATH | Christen Andersen | Received |
823-P | CHRONIC MYELOPROLIFERATIVE NEOPLASMS REVEAL INCREASED RISK OF OSTEOPOROTIC FRACTURES | Sarah Farmer | Received |
824-P | DETERMINANTS AND FREQUENCY OF THROMBOTIC AND BLEEDING COMPLICATIONS IN AN ITALIAN COHORT OF 88 PATIENTS WITH PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS (MPN): THE ROLE OF ADAMTS-13 AND VWF ACTIVITIES | Augusto B Federici | Received |
825-P | INTERNATIONAL PROGNOSTIC SCORE FOR ESSENTIAL THROMBOCYTHEMIA (IPSET) AND IPSET-THROMBOSIS ONE CENTRE ANALYSIS | TERESA GARRIDO | Received |
826-P | BCR/ABL EXPRESSION IN CHRONIC MYELOPROLIFERATIVE DISORDERS | Laura Kesaeva | Received |
827-P | A CASE STUDY OF RESENSITIZATION TO RUXOLITINIB, A JAK1/JAK2 INHIBITOR, IN A PATIENT WITH MYELOFIBROSIS (MF) | Jessica Litvan | Received |
829-P | ADDITION OF THE DEGREE OF BONE MARROW FIBROSIS TO IPSS IN NEW SCORING SYSTEM IMPROVES PREDICTION OF SURVIVAL IN PRIMARY MYELOFIBROSIS | Danijela Lekovic | Received |
830-P | CONTRIBUTION OF SNP ARRAYS TO THE DIAGNOSIS AND PROGNOSIS OF CMML. A STUDY OF PATIENTS WITH LOW RISK CYTOGENETIC FEATURES AND CASES WITH ABSENCE OF METAPHASES | Laura Palomo | Received |
832-P | HIGHLY SPECIFIC QPCR ASSAYS USING CONSENSUS LNA PROBE FOR THE DETECTION OF t(11;14) AND t(14;18) IN NON-HODGKIN LYMPHOMA WITH A SENSITIVITY OF 10-5 FOR QUANTIFICATION OF MINIMAL RESIDUAL DISEASE | Camilla Darum Srensen | Received |
834-P | NR4A1 MEDIATED APOPTOSIS SUPPRESSES LYMPHOMAGENESIS IN A XENOGRAFT MOUSE MODEL | Alexander Deutsch | Received |
835-P | EZH2 EXPRESSION DETERMINED BY IMMUNOHISTOCHEMISTRY DOES NOT CORRELATE WITH THE PRESENCE OF EZH2 MUTATIONS IN A SERIES OF DIFFUSE LARGE B-CELL LYMPHOMAS (DLBCL) | Mar Garcia | Received |
836-P | DLBCL BIOLUMINESCENT XENOGRAFT MODEL FOR NON-INVASIVE FOLLOW-UP OF ANTITUMOR EFFECT | María José Moreno Jiménez | Received |
837-P | BLOOD AND LYMPHATIC MICROENVIRONMENT, MACROPHAGE COMPONENT AS PROGNOSTIC MARKERS IN FOLLICULAR LYMPHOMA | Ekaterina Nesterova | Received |
841-P | IDENTIFICATION OF DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) SUBTYPES DEFINED BY THE EXPRESSION OF STROMAL PROTEINS AND THEIR ASSOCIATION WITH MICRORNAS INVOLVED IN ANGIOGENESIS | Natália Borges | Received |
842-P | DISTINCT GENE EXPRESSION PROFILES IN A CANINE MODEL OF HUMAN DLBCL | Geertruy te Kronnie | Received |
844-P | CLINICAL SYMPTOM OR SIGN-DIRECTED SURVEILLANCE CAN BE MORE USEFUL TO DETECT RELAPSE COMPARED TO ROUTINE IMAGING IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA AFTER COMPLETE REMISSION | Junshik Hong | Received |
845-P | VIROLOGICAL SUCCESS IS ASSOCIATED WITH FAVORABLE PROGNOSIS IN PATIENTS WITH HEPATITIS C ASSOCIATED B-CELL NON-HODGKIN LYMPHOMAS, NATIONAL ANRS HC-13 LYMPHO-C STUDY RESULTS. | Jean Marie Michot | Received |
847-P | HIGH-DOSE METHOTREXATE, HIGH-DOSE CYTARABINE AND TEMOZOLOMIDE FOR THE TREATMENT OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA | maher salamoon | Received |
850-P | LENALIDOMIDE PLUS RITUXIMAB-CHOP21 IN ELDERLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA IS PROMISING: LONG TERM RESULTS OF THE PHASE II REAL07 STUDY OF THE FONDAZIONE ITALIANA LINFOMI (FIL) | Annalisa Chiappella | Received |
851-P | PHASE 1B STUDY COMBINING IBRUTINIB WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, AND PREDNISONE (R-CHOP) IN PATIENTS WITH CD20-POSITIVE B-CELL NON-HODGKIN LYMPHOMA (NHL) | Pam Milner | Received |
852-P | PROSPECTIVE COHORT STUDY FOR SECONDARY CENTRAL NERVOUS SYSTEM INVOLVEMENT IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS TREATED WITH RITUXIMAB-CHOP | Seok Jin Kim | Received |
853-P | INTERIM PET-CT SCAN AFTER 2 CYCLES SUCCESSFULLY PREDICTS OUTCOME IN DLBL BUT INTRODUCES SIGNIFICANT SELECTION BIAS. | Nicholas Grigoropoulos | Received |
854-P | STAGING NEWLY DIAGNOSED LYMPHOMAS: COMPARISON BETWEEN WHOLE BODY-MRI/DWIBS AND 18FDG-PET/CT | Carla Minoia | Received |
855-P | CENTRAL NERVOUS SYSTEM RELAPSE IN NON HODGKIN LYMPHOMA: PROGNOSTIC FACTORS AND OUTCOME IN A COHORT OF 304 PATIENTS | Juanjosé Alonso | Received |
856-P | LYMPHOCYTE COUNT AT DIAGNOSIS IN DIFFUSE LARGE B-CELL LYMPHOMA IN THE ERA OF IMMUNOCHEMOTHERAPY WITH RITUXIMAB: IS 1000/MM3 STILL THE BEST CUT-OFF VALUE TO USE TO DEFINE LYMPHOPENIA ? | Alessia Bari | Received |
859-P | PROGNOSTIC FACTORS IN VERY OLD PATIENTS (= 75 YEARS) WITH FOLLICULAR LYMPHOMA: A MULTICENTRE RETROSPECTIVE STUDY | Anne Parcelier | Received |
860-P | EFFICACY AND SAFETY OF LENALIDOMIDE WITH/WITHOUT RITUXIMAB OR STEROIDS IN HEAVILY PRETREATED NON-HODGKINS B-CELL LYMPHOMAS: RESULTS OF A RETROSPECTIVE STUDY | ANNALISA CHIAPPELLA | Received |
862-P | SERUM FREE LIGHT CHAINS LEVELS IN PATIENTS WITH HIV-RELATED LYMPHOMA ARE LOWER AT COMPLETE RESPONSE THAN AT DIAGNOSIS | Maria Joao Baptista | Received |
863-P | PROGNOSTIC RELEVANCE OF FDG-PET IN PATIENTS WITH PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA | Gayane Tumyan | Received |
864-P | FC-GAMMA-RECEPTOR IIIA POLYMORPHISM AND GENE EXPRESSION PROFILE DO NOT INFLUENCE TREATMENT OUTCOMES AND SURVIVAL IN DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH R-CHOP PROTOCOL | Laszlo Varoczy | Received |
865-P | INTENSIFIED PROGRAM INCLUDING BENDAMUSTINE, HIGH DOSE THERAPY AND AUTOGRAFT FOR PATIENTS WITH RELAPSED OR RESISTANT FOLLICULAR NON HODGKIN LYMPHOMA: RESULTS FROM AN EXPLORATORY GITIL STUDY | Caterina Patti | Received |
866-P | THE INTENSITY AND DURATION OF PAIN ASSOCIATED WITH TREPHINE BIOPSY | Waleed Ghanima | Received |
869-P | THE ROLEOF PET/CT FOR EVOLUATION OF THE BONE MARROW INVOLVEMENT IN LYMPHOMA PATIENTS | asu fergun yilmaz | Received |
870-P | ANALYSIS OF THE BONE MARROW INFILTRATION IN A GROUP OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA BY COMPARING BONE MARROW BIOPSY AND 18F-FDG PET/CT | Paula César | Received |
871-P | COMPARISONS OF B-CELL AND T-CELL LYMPHOMA-ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS | Jui-Ting Yu | Received |
873-P | HIGH DOSE THERAPY WITH AUTOLOGOUS STEM CELL SUPPORT FOR PRIMARY CNS LYMPHOMA: A RETROSPECTIVE ANALYSIS FROM THE ADULT LYMPHOMA WORKING GROUP OF THE JAPAN SOCIETY FOR HEMATOPOIETIC CELL TRANSPLANTATION | Eisei Kondo | Received |
874-P | A MULTICENTRE REVIEW OF THE OUTCOMES OF PATIENTS ABOVE THE AGE OF 75 WITH PRIMARY DIFFUSE LARGE B CELL LYMPHOMA | Vikramajit Singh | Received |
875-P | HUMAN CORD BLOOD CD45 CELLS PROTECT MICE BRAIN AFTER CLOSED HEAD INJURY | Hadar Arien-Zakay | Received |
876-P | PYROSEQUENCING IS A NEW PROMISING APPROACH TO PERFORM HLA TYPING IN A QUICKLY, SIMPLE AND ACCURATE WAY | Federica Cattina | Received |
878-P | DIFFERENT DOSE OF ATG INDUCTION THERAPY IN HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION: LONG TERM EFFECT ON TH17 AND CONVENTIONAL T CELLS, NOT ON NK RESPONSES | Xiang-Yu Zhao | Received |
879-P | CIRCULATING ENDOTHELIAL CELLS (CEC) ARE A RELIABLE AND DYNAMIC BIOMARKER OF ACUTE GVHD (AGVHD) IN PATIENTS UNDERGOING ALLOGENEIC STEM CELLS TRANSPLANTATION. | Andrea Di Palma | Received |
880-P | EFFECT OF GRANULOCYTE COLONY-STIMULATING FACTOR MOBILIZATION ON THE EXPRESSION OF REGULATORY GAMMA DELTA T CELLS | Qifa Liu | Received |
883-P | PARALEL STUDY OF CHIMERISM AFTER ALLOGENIC HAEMTOPOIETIC STEM CELL TRANSPLANTATION MONITORED BY TWO DIFFERENT MOLECULAR METHODS | Eva Hanusovska | Received |
884-P | VENO-OCCLUSIVE DISEASE MAY DEVELOP IN SECONDARY IRON OVERLOADED MICE AFTER TOTAL BODY IRRADIATION. | Dae Chul Jeong | Received |
887-P | STUDY OF SOLUBLE HLA-G LEVEL DYNAMICS IN HEMATOLOGICAL PATIENTS UNDERGOING AUTOLOGOUS OR ALLOGENEIC STEM CELL TRANSPLANTATION | Elena Ribakovsky | Received |
889-P | CONTROLLED EPSTEIN-BARR VIRUS REACTIVATION AFTER ALLOGENIC TRANSPLANTATION IS ASSOCIATED WITH IMPROVED SURVIVAL ASSOCIATED TO AN EXPANSION OF NATURAL KILLER CELLS (NK). | JEAN FRANCOIS ROSSI | Received |
890-P | MYELOABLATIVE FLUDARABINE PLUS BUSULFAN IV (FB4) REGIMEN COMPARES FAVOURABLY WITH CYCLOPHOSPHAMIDE PLUS BUSULFAN (BUCY) IN PATIENTS UNDERGOING ALLO-SCT FOR MYELOID MALIGNANCY | Valerie COITEUX | Received |
891-P | LONG-TERM OUTCOME (BEYOND 10 YEARS) AFTER ALLOGENEIC STEM-CELL TRANSPLANTATION WITH REDUCED-INTENSITY COMPARED TO MYELOABLATIVE CONDITIONING; SIMILAR SURVIVAL BUT DIFFERENT PATTERN OF LATE EVENTS | Avichai Shimoni | Received |
892-P | HOW MANY AML PATIENTS DO RECEIVE EARLY ALLOGENEIC BONE MARROW TRANSPLANT AND WHICH TRANSPLANT IS PERFORMED? REAL LIFE DATA FROM GENOVA ACUTE LEUKEMIA REGISTRY (REGAL). | Marino Clavio | Received |
893-P | THE MANAGEMENTS OF EBV-ASSOCIATED POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER WITH CENTRAL NERVOUS SYSTEM INVOLVEMENT AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION | Qifa Liu | Received |
894-P | ASSOCIATION OF HLA POLYMORPHISMS WITH EPSTEIN-BARR VIRUS INFECTION AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION | Qifa Liu | Received |
895-P | PERFORMANCE OF FECAL CALPROTECTIN FOR THE DIAGNOSIS AND FOLLOW UP OF ACUTE GASTRO-INTESTINAL GRAFT VERSUS HOST DISEASE | Marta Lisa Battista | Received |
896-P | IMMUNOPHENOTYPIC RESPONSE AFTER ALLOGRAFTING IN MULTIPLE MYELOMA | Luisa Giaccone | Received |
898-P | THREE DAYS BUSULFAN ASSOCIATED WITH FLUDARABINE AND ANTITHYMOGLOBULINE CONDITIONING: IS IT SAFE? | Sylvain Chantepie | Received |
899-P | IMPROVED OUTCOME WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION IN A POOR PROGNOSTIC SUBGROUP OF PATIENTS WITH MIXED-LINEAGE-LEUKEMIAREARRANGED LEUKEMIA: RESULTS FROM A SINGLE-CENTER PROSPECTIVE STUDY | yu wang wang | Received |
902-P | MOBILIZATION AND ENGRAFTMENT OF PERIPHERAL BLOOD STEM CELLS IN RELATED HEALTHY DONORS OLDER THAN 55 YEARS | Cristina Motlló | Received |
903-P | EFFICACY OF ORAL BUDESONIDE FOR GASTROINTESTINAL GRAFT VERSUS HOST DISEASE IN HAEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS | Mui Fong Chong | Received |
905-P | MYELOABLATIVE CONDITIONING REGIMEN WITHOUT ATG AND TBI IN SINGLE UNIT UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION WITH HEMATOLOGIC MALIGNANCIES | Juan Tong | Received |
907-P | IMPACT OF INAPPROPRIATE MICAFUNGIN PROPHYLAXIS IN A BONE MARROW TRANSPLANTATION (BMT) UNIT ON THE OUTCOME OF CANDIDIASIS AND ON THE EMERGENCE OF ECHINOCANDIN-RESISTANT CANDIDA KRUSEI ISOLATES | Emmanuelle Tavernier | Received |
909-P | SIMILAR OUTCOMES BETWEEN YOUNGER AND OLDER AGE GROUP IN ADULT PATIENTS WITH SEVERE APLASTIC ANEMIA WHO RECEIVED HLA-MATCHED SIBLING TRANSPLANTS WITH FLUDARABINE-BASED CONDITIONING | Seung Hwan Shin | Received |
910-P | POORER OUTCOME AFTER CORD BLOOD THAN AFTER MATCHED RELATED OR UNRELATED DONOR ALLOGENEIC STEM CELL TRANSPLANTATION PREPARED WITH REDUCED TOXICITY CONDITIONING FOR HIGH RISK ACUTE MYELOID LEUKEMIA | devillier raynier | Received |
912-P | KIR-LIGAND INCOMPATIBILITY IN THE GRAFT-VERSUS-HOST DIRECTION DID NOT AFFECT OUTCOMES OF SINGLE UMBILICAL CORD BLOOD TRANSPLANTATION WITHOUT ATG FOR ACUTE LEUKEMIA IN COMPLETE REMISSION | Junji Tanaka | Received |
914-P | PROGNOSTIC IMPACT OF CHRONIC GRAFT VERSUS HOST DISEASE IN PATIENTS WITH MYELOID NEOPLASMS UNDERGOING REDUCED INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION A SINGLE INSTITUTION SERIES | Desire Gijima | Received |
915-P | IN VIVO T-CELL DEPLETION WITH LOW-DOSE ANTITHYMOCYTE GLOBULIN TO REDUCE ACUTE GVHD IN UNRELATED DONOR STEM CELL TRANSPLANT FOR PATIENTS WITH SEVERE APLASTIC ANEMIA | Sung-Eun Lee | Received |
916-P | IMPACT OF ABO INCOMPATIBILITY ON UNRELATED CORD BLOOD TRANSPLANTATION | Yao Wen | Received |
917-P | SECONDARY ANTIFUNGAL PROPHYLAXIS BASED ON RESPONSE TO INITIAL ANTIFUNGAL THERAPY FOR PATIENTS WITH A HISTORY OF INVASIVE PULMONARY ASPERGILLOSIS IN ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION | Qifa Liu | Received |
918-P | A MONOCLONAL PROTEIN FOUND IN RELATED STEM CELL DONORS: ARE WE DOING IT RIGHT? | Nicolette Tiren-Verbeet | Received |
919-P | TBI AND CYCLOPHOSPHAMIDE PLUS ATG IS WELL TOLERATED AND EFFECTIVE AS A PREPARATIVE REGIMEN FOR HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITHOUT IN VITRO T-CELL DEPLETION | Haixia Fu | Received |
920-P | HIGH LEVEL OF VASCULAR ENDOTHELIAL GROWTH FACTOR IS ASSOCIATED WITH INCREASED RELAPSE RATE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION | Ivan Moiseev | Received |
921-P | CLINICAL IMPACT OF ENGRAFTMENT SYNDROME IN ADULT PATIENTS WHO RECEIVED ALLOGENEIC STEM CELL TRANSPLANTATION | Hiroaki Shimizu | Received |
924-P | THERAPEUTIC APPROACH TO RELAPSE OF PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION | Claudia Moreira | Received |
925-P | IMPACT OF THE 2009 UK UMBILICAL CORD BLOOD TRANSPLANT CONSENSUS STATEMENT ON PRACTICE AND OUTCOMES AT A SINGLE TRANSPLANT CENTRE | chloe anthias | Received |
926-P | CMV-SPECIFIC CD8 T-CELL IMMUNE RECOVERY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION MONITORED BY HLA-MULTIMERS | EDUARDO OLAVARRIA | Received |
927-P | IDENTIFICATION OF THE EARLIEST BRANCH POINT FOR MYELO-ERYTHROID DEVELOPMENT IN ADULT HEMATOPOIESIS | Kohta Miyawaki | Received |
932-P | Studies of JARID1B in Hematopoiesis Using Gene Knockdown and Overexpression Assay | Jingxuan Zhang | Received |
933-P | ROLE OF BMI-1 IN NORMAL MOUSE HEMATOPOIETIC STEM CELLS AND LEUKEMIC CELLS | Yuk Man Lam | Received |
934-P | CONNECTIVE TISSUE GROWTH FACTOR (CTGF) CONFERS CELL ADHESION-MEDIATED DRUG-RESISTANCE (CAM-DR) IN ACUTE MYELOID LEUKEMIA | Saskia Pante | Received |
935-P | HUMAN BONE MARROW ADIPOCYTES MAINTAIN THE SURVIVAL AND DIFFERENTIATION OF HEMATOPOIETIC STEM CELLS | Giulia Maurizi | Received |
937-P | ANALYSIS OF HUMAN ENDOSTEAL HSC NICHE; A NOVEL POPULATION WITH HIGH EXPRESSION OF CD34 AND ESAM IS ADJACENT TO TRABECULAR AREAS OF HUMAN BONE MARROW | MICHIKO ICHII | Received |
938-P | HEAD-TO-HEAD COMPARATIVE STUDY OF WHARTONS JELLY AND BONE MARROW MESENCHYMAL STEM CELLS | Charalampos Pontikoglou | Received |
939-P | ALTERATION IN GENE EXPRESSION PATTERN IN STROMAL PRECURSOR CELLS OF PATIENTS BEFORE AND AFTER ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANTATION | Irina Shipounova | Received |
940-P | ROLE OF BONE MARROW STROMAL CELLS IN THE REGULATION OF HUMAN EARLY LYMPHOPOIESIS | Kohshi Ohishi | Received |
941-P | DEREGULATION OF PI3K/AKT SIGNALING IN BONE MARROW MESENCHIMAL STROMAL CELLS FROM PATIENTS WITH DE NOVO AND THERAPY-RELATED ACUTE MYELOID LEUKEMIA | Francesco Dalň | Received |
943-P | UMBILICAL CORD MESENCHYMAL STEM CELLS WITH IMPROVED SUPPORT FOR HEMATOPOIETIC STEM CELL EXPANSION. | Pavel Butylin | Received |
944-P | ENDOTHELIAL CELLS EXPRESSING CONSTITUTIVELY ACTIVE AKT1 ARE CAPABLE OF RECONSTITUTING OF VASCULAR NICHE IN VITRO. | Pavel Butylin | Received |
945-P | CHEMOKINE SIGNALLING REGULATES HAEMOPOIETIC STEM CELL PROPERTIES | Amy Sinclair | Received |
947-P | MONOALLILIC MUTATIONS OF FHL-RELATED GENES PREDISPOSE TO MACROPHAGE ACTIVATION SYNDROME | Elena Sieni | Received |
949-P | COMBINED APPLICATION OF MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION AND FLUORESCENCE IN SITU HYBRIDIZATION TO DETECT CYTOGENETIC ABNORMALITIES IN MULTIPLE MYELOMA | Donat Alpar | Received |
950-P | COMPARISON OF MICROARRAY-BASED GENOMIC PROFILING AND MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION (MLPA) FOR THE DETECTION OF CLINICALLY RELEVANT GENETIC LESIONS, INCLUDING IKZF1, IN ALL | Marian Stevens-Kroef | Received |
955-P | ARRAY-BASED GENOMIC PROFILING IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IDENTIFIES HIGHER NUMBER OF PROGNOSTIC RELEVANT GENOMIC ALTERATIONS AND REVEALS NEW RECURRENT GENOMIC ABNORMALITIES | Marian Stevens-Kroef | Received |
956-P | DEREGULATION OF STEM CELL FACTOR (SCF)-AKT-S6 PATHWAY IN DIAGNOSTIC AML SAMPLES IS ASSOCIATED WITH DISEASE-FREE SURVIVAL: RESULTS OF A VERIFICATION STUDY | Michelle Atallah | Received |
957-P | HIGH-RESOLUTION GENOMIC PROFILING IN MULTIPLE MYELOMA IDENTIFIES RECURRENT PROGNOSTIC RELEVANT COPY NUMBER ALTERATIONS AND REVEALS NEW RECURRENT GENOMIC ABNORMALITIES | Marian Stevens-Kroef | Received |
959-P | IMPORTANCE OF MICROARRAY ANALYSIS AS A PROGNOSTIC CLINICAL TOOL IN CHRONIC LYMPHOCYTIC LEUKEMIA | Nolwen Prie | Received |
961-P | CHARACTERISTICS OF VARIANT AND ADDITIONAL CYTOGENETIC ABNORMALITIES IN ACUTE MYELOID LEUKEMIA WITH RECURRENT GENETIC ABNORMALITIES | Eunhae Cho | Received |
962-P | MUTATIONAL STUDY OF DNMT3A IN ACUTE MYELOID LEUKEMIA | Seung Hwan Oh | Received |
965-P | EX VIVO SENSITIVITY AND RESISTANCE MECHANISMS TO CLOFARABINE IN CHILDHOOD ACUTE LEUKEMIA | Baleydier Frederic | Received |
967-P | TRANSCRIPT LEVELS AND COPY NUMBER VARIATION OF THE ABCC3 EFFLUX TRANSPORTER CAN PREDICT CLINICAL OUTCOME IN IMATINIB-TREATED CHRONIC MYELOID LEUKAEMIA PATIENTS | Athina Giannoudis | Received |
968-P | TARGETING THE DBC1-SIRT1-P53 AXIS IS A PROMISING THERAPEUTIC STRATEGY IN FLT3-ITD-POSITIVE AML | Daniel Sasca | Received |
969-P | TRANSCRIPTIONAL PROGRAMMES ASSOCIATED WITH EVI1 MEDIATED CHEMOTHERAPY RESISTANCE OF HUMAN MYELOID CELLS | Rotraud Wieser | Received |
970-P | KNOCKDOWN OF NUCLEOPHOSMIN BY RNA INTERFERENCE REVERSES MULTIDRUG RESISTANCE IN RESISTANT LEUKEMIC HL-60 CELLS | Jianda Hu | Received |
972-P | POLYMORPHISMS OF MULTIDRUG RESISTANCE TRANSPORTER (ABCG2 AND ABCB1) GENES IN PATIENTS WITH ACUTE MYELOID LEUKAEMIA | Hajnalka Andrikovics | Received |
976-P | EVIDENCE THAT THE PREGNANE X AND RETINOID RECEPTORS PXR, RAR AND RXR MAY REGULATE TRANSCRIPTION OF THE IMATINIB TRANSPORTER HOCT1 EXPRESSION IN CHRONIC MYELOID LEUKAEMIA CELLS | Lihui Wang | Received |
977-P | THE ROLE OF CYP2J2 IN CYCLOPHOSPHAMIDE METABOLISM | Ibrahim El-Serafi | Received |
978-P | ABCB1 HAPLOTYPE IS ASSOCIATED WITH ALTERATIONS IN FUNCTIONAL ACTIVITY OF P-GP AND AFFECTS MAJOR MOLECULAR RESPONSE IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH STANDARD-DOSE OF IMATINIB | Douglas Vivona | Received |
979-P | DIAGNOSTIC AND THERAPEUTIC POTENTIALS OF EXPRESSION LEVELS OF BIOACTIVE SPHINGOLIPID GENES IN NEWLY DIAGNOSED AND DRUG-RESISTANT CHRONIC MYELOID LEUKEMIA PATIENTS | Yusuf Baran | Received |
980-P | SMO INHIBITOR SPECIFICALLY TARGETS THE HEDGEHOG PATHWAY AND REVERTS THE DRUG-RESISTANCE OF LEUKEMIC STEM CELLS | viviana guadagnuolo | Received |
983-P | CHARACTERIZATION OF THE PHARMACOKINETIC AND PHARMACODYNAMIC PROPERTIES OF PACRITINIB (SB1518), A NOVEL ORAL JAK2/FLT3 INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS, AML AND LYMPHOMA | Kristin MacIntosh | Received |
987-P | PULMONARY EFFECTS OF PERFLUOROCARBON EMULSION THERAPY ON INFECTED SICKLE CELL MICE | Nawal Helmi | Received |
988-P | THE BTK-SPECIFIC INHIBITOR ONO-4059 SYNERGIZES WITH THE BCL2 INHIBITOR ABT-263. | Martin Dyer | Received |
989-P | EFFICIENCY OF CD19 TARGETING BY MONOCLONAL ANTIBODIES IN EX VIVO AND MOUSE MODELS OF CHILDREN ACUTE B-LYMPHOBLASTIC LEUKEMIAS | Arthur Dony | Received |
990-P | INFLUENCE OF HISTONE DEACETYLASE INHIBITORS (HDACI) ON CD20 EXPRESSION AND EFFICACY OF ANTI-CD20 MONOCLONAL ANTIBODIES | Malgorzata Wanczyk | Received |
991-P | BOTANICAL ALKYL HYDROQUINONE HQ17(3) EXHIBITS CYTOTOXIC EFFECT ON SUP-B15 ALL CELLS HARBORING T(9;22) PHILADELPHIA CHROMOSOME THROUGH INDUCING IRON-DEPENDENT LYSOSOMAL EVENTS AND OXIDATIVE STRESS | Chung-Yi Hu | Received |
995-P | THE DONOR DEPENDENT IMMUNE MODULATORY POTENTIAL OF MESENCHYMAL STROML CELL PREPARATIONS CAN BE PREDICTED BY GALECTIN-9 | Christopher Ungerer | Received |
996-P | INCREASING SAFETY AND EFFICACY OF TCR TRANSFER BY EMPLOYING A MINIMALLY MURINIZED HUMAN TUMOR-REACTIVE SINGLE-CHAIN TCR | Beate Hauptrock | Received |
998-P | STAINING OF ANTIGEN-SPECIFIC CD4 T CELLS USING MHC CLASS II TETRAMERS GENERATED ACCORDING TO A NOVEL METHOD OF PEPTIDE-MHC CLASS II MONOMER PRODUCTION AND PURIFICATION | Peter Braendstrup | Received |
999-P | PMHC ARRAYS DEMONSTRATE THAT UNTOUCHED T CELL POPULATIONS FROM PRESENTATION ACUTE MYELOID LEUKAEMIA PATIENTS PREDOMINANTLY RECOGNIZE THE CANCER-TESTIS ANTIGEN, PASD1 | Barbara Guinn | Received |
1000-P | CYTOKINE INDUCED KILLER CELLS ARE ACTIVE AGAINST NON-SMALL CELL LUNG CANCER AND OVERCOME THE ACQUIRED RESISTANCE TO TARGET THERAPIES | Maja Todorovic | Received |
1002-P | NATURAL KILLER CELL EXPANSION UNDER GOOD MANUFACTURING PRACTICE CONDITIONS FOR CLINICAL USE IN ADULT PHILADELPHIA ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS | Nadia Peragine | Received |
1003-P | EFFICIENT GENERATION OF HLA-A2 AND A24-RESTRICTED WT1-SPECIFIC CYTOTOXIC T LYMPHOCYTES USING GENE-ENGINEERED ARTIFICIAL ANTIGEN-PRESENTING CELLS | Masahiro Ogasawara | Received |
1004-P | OPTIMIZATION OF ALLOGENEIC NK CELLS FOR ADOPTIVE TRANSFER THERAPY | Michal Besser | Received |
1007-P | CENTRALIZED PRODUCTION AND DISTRIBUTION OF CMV-SPECIFIC CYTOTOXIC T CELL LYMPHOCYTES | Anke Friedetzky | Received |
1008-P | LAK CELLS AND ANTI-CD20 MONOCLONAL ANTIBODIES AS INMUNOTHERAPY ON FOLLICULAR LYMPHOMA: ENCHANCED ANTIBODY-DEPENDENT CELL CITOTOXICITY OF LAK CELLS IN ASSOCIATION WITH GA101 RATHER THAN RITUXIMAB | Alfonso Piérola Ana | Received |
1009-P | ROLE OF CIRCULATING &945;&946;-DOUBLE NEGATIVE T CELLS (DNT) IN LYMPHOMA PATIENTS: PRELIMINARY RESULTS OF A PROSPECTIVE STUDY | Giacoma De Tullio | Received |
1010-P | EFFECT OF HISTONE METHYLTRANSFERASE EZH2 INHIBITOR 3-DEAZANEPLANOCIN A (DZNEP) ON ERYTHROPOIESIS | Tohru Fujiwara | Received |
1011-P | Locus Control Region in the HBB globin cluster: HS3 deletion has a very limited effect over adult globin gene expression | Felix De La Fuente | Received |
1013-P | INHIBITION OF ERYTHROPOIESIS THROUGH HEPCIDIN AND ROS IN TRANSFUSION-RELATED IRON OVERLOAD MICE | MASAYOSHI MASUKO | Received |
1014-P | CONGENITAL DYSERYTHROPOIETIC ANEMIA DUE TO A NOVEL GATA-1 MUTATION | Janet Pereira | Received |
1015-P | EFFECTS OF CHRONIC PSYCHOLOGICAL STRESS ON EXTRAMEDULLARY ERYTHROPOIESIS: INVOLVEMENT OF EPOR, GR, C-KIT AND BMP4 SIGNALING | Mirela Budec | Received |
1016-P | DOES THE OPTICAL MICROSCOPE TELL US THE COMPLETE STORY IN MEMBRANE-CYTOSKELETON DISORDERS? A STUDY OF RED BLOOD CELLS WITH ATOMIC-FORCE AND SCANNING-ELECTRON MICROSCOPES IN HEREDITARY SPHEROCYTOSIS | Dimosthenis Stamopoulos | Received |
1017-P | INVESTIGATION OF HEMORHEOLOGICAL PARAMETERS AT THE DIAGNOSIS AND THE FOLLOW-UP OF NUTRITIONAL VITAMIN B12 DEFICIENT CHILDREN | Hazal Tancer-Eli | Received |
1018-P | X-LINKED SIDEROBLASTIC ANEMIA: A PROMOTER MUTATION IN THE ALAS2 GENE | Janet Pereira | Received |
1022-P | IMMUNOGENICITY OF LIPEGFILGRASTIM AND PEGFILGRASTIM IN BREAST CANCER PATIENTS RECEIVING CHEMOTHERAPY: INTEGRATED ANALYSIS FROM PHASE II AND III STUDIES | Afsaneh Abdolzade-Bavil | Received |
1024-P | LIPEGFILGRASTIM A LONG-ACTING, ONCE-PER-CYCLE, GLYCOPEGYLATED RECOMBINANT HUMAN FILGRASTIM CREATED WITH SITE-SPECIFIC GLYCOPEGYLATION TECHNOLOGY | Christian Scheckermann | Received |
1025-P | SAFETY AND TOLERABILITY OF LIPEGFILGRASTIM IN BREAST CANCER PATIENTS RECEIVING CHEMOTHERAPY: AN INTEGRATED ANALYSIS OF PHASE II AND III STUDIES | Oleg Gladkov | Received |
1026-P | CARDIAC INVOLVEMENT IN TYPE 3 EGYPTIAN GAUCHER DISEASE PATIENTS: A REPORT OF 7 CASES AND A NEWLY REPORTED ANOMALY | Magy Abdelwahab | Received |
1027-P | A FEASIBILITY STUDY OF HOME MONITORING OF BLOOD NEUTROPHIL COUNTS IN PATIENTS WITH CHRONIC NEUTROPENIA | David Dale | Received |
1029-P | LANGERHANS CELL HISTEOCYTOSIS (LCH) IN EGYPTIAN CHILDREN. A SINGLE CENTER EXPERIENCE. | Sedky Mohamed Sedky | Received |
1030-P | PEGFILGRASTIM AS PROPHYLAXIS OF FEBRILE NEUTROPENIA DURING CHEMOTHERAPY OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA | Claudio Cerchione | Received |
1031-P | CHRONIC BENIGN NEUTROPENIA IN ADULTS: LABORATORY AND CLINICAL PARAMETERS OF A 6-YEAR FOLLOW-UP | BRUNO FATTIZZO | Received |
1034-P | LANGERHANS CELL HISTIOCYTOSIS: ONE CENTER EXPERIENCE BETWEEN 1990-2012 | Tulin Tiraje Celkan | Received |
1035-P | A NEW TYPE OF CHEDIAK-HIGASHI SYNDROME? CASE REPORT OF A BLACK HAIRED GIRL WITHOUT OCULOCUTANEUS ALBINISM PRESENTED WITH EARLY ONSET HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS | Halil Ugur Hatipoglu | Received |
1036-P | CHEMOTHERAPY-ASSOCIATED TREATMENT BURDEN IN BREAST CANCER PATIENTS RECEIVING LIPEGFILGRASTIM OR PEGFILGRASTIM: SECONDARY EFFICACY DATA FROM A PHASE III STUDY | Oleg Gladkov | Received |
1037-P | USE OF ROMIPLOSTIM IN PATIENTS WITH CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA (CITP) DURING PERI-OPERATIVE PERIOD | William Alexander | Received |
1039-P | A MULTICENTER OBSERVATIONAL STUDY FOR EARLY DIAGNOSIS OF GAUCHER DISEASE IN PATIENTS WITH SPLENOMEGALY AND/OR THROMBOCYTOPENIA | Irene Motta | Received |
1040-P | A RETROSPECTIVE ANALYSIS OF EPSILON-AMINO-CAPROIC ACID THERAPY IN HYPOPROLIFERATIVE THROMBCYTOPENIA | Shweta Jain | Received |
1041-P | THE USE OF MYCOPHENOLATE MOFETIL IN THE TREATMENT OF CHRONIC REFRACTORY IMMUNE THROMBOCYTOPENIA PURPURA | Alice Taylor | Received |
1043-P | DURATION OF BLEEDING SYMPTOMS 14 DAYS BEFORE DIAGNOSIS IS A STRONG PREDICTOR FOR DEVELOPMENT OF CHRONICITY IN CHILDHOOD PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) | Andromachi Papagianni | Received |
1044-P | PLATELET ACTIVATION MARKERS IN PATIENTS WITH INCREASED CARDIOVASCULAR RISK | Gavriilaki Eleni | Received |
1046-P | THROMBOCYTOPENIA PREDICT MORTALITY IN CRITICALLY ILL PATIENTS | Emel Gurkan | Received |
1049-P | THE IMMATURE PLATELET FRACTION IS SENSITIVE TO THE PLATELET SIZE AND A USEFUL PARAMETER FOR SCREENING FOR MACROTHROMBOCYTOPENIA | Miyazaki Koji | Received |
1052-P | OVERVIEW OF RUSSIAN PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) REGISTRY | Igor Lisukov | Received |
1053-P | DIFFERENTIAL DIAGNOSIS OF THROMBOTIC MICROANGIOPATHY: DATA FROM PADOVA TTP CASE SERIES | Giulia Berti de Marinis | Received |
1055-P | EXTREME THROMBOCYTOSIS ( 1000 X 109 /L) IN 336 PATIENTS- REPORT OF A FOUR-YEAR EXPERIENCE | Emmanouil Papadakis | Received |
1056-P | ANTIPLASMIN, BUT NOT AMILORIDE, PREVENTS SYNOVITIS AND CARTILAGE DESTRUCTION FOLLOWING HEMARTHROSIS IN HEMOPHILIC MICE | laurens nieuwenhuizen | Received |
1058-P | MOLECULAR DIAGNOSTIC IN 47 UNRELATED FAMILIES WITH HAEMOPHILIA A IN ARAGON (SPAIN) | Silvia Santa Catalina | Received |
1059-P | IMPAIRED PROPLATELET FORMATION IN A NOVEL GLANZMANN VARIANT MACROTHROMBOCYTOPENIA | Koji Miyazaki | Received |
1060-P | MUTATION ANALYSIS IN TURKISH RARE BLOOD DISORDERS | D&304;DEM TORUN | Received |
1062-P | HOW DO WE ENCOUNTER RARE FACTOR DEFICIENCIES IN CHILDREN? SINGLE CENTER RESULTS | Zafer Salcioglu | Received |
1066-P | ACQUIRED VON WILLEBRAND SYNDROME AND MONOCLONAL GAMMOPATHY: CLINICAL CHARACTERIZATION AND RECOVERY TO INFUSION OF VWF-CONTAINING CONCENTRATES | Chiara Ambaglio | Received |
1067-P | VENOUS THROMBOEMBOLISM (VTE) PROPHYLAXIS IN HOSPITALIZED OBSTETRIC PATIENTS : A MULTICENTRE CROSS-SECTIONAL STUDY | Maeve Crowley | Received |
1068-P | INVESTIGATION TO IMPROVE DETECTION OF LUPUS ANTICOAGULANT IN A LOCAL POPULATION EXPERIENCING RECURRENT MISCARRIAGE AND INTRAUTERINE DEATH | Ailin McMahon | Received |
1070-P | THROMBOSIS IN CHILDHOOD ACUTE LEUKEMIA | yaman yntem | Received |
1072-P | ULTRASTRUCTURAL ANALYSES OF THE NOVEL CHIMERIC HEMOSTATIC AGENT GENERATED VIA NANOTECHNOLOGY, ABS NANOHEMOSTAT, AT THE RENAL TISSUE LEVEL | Ibrahim Haznedaroglu | Received |
1073-P | MORTALITY OF PATIENTS WITH HEMATOLOGICAL MALIGNANCIES AND RELATION TO COAGULATION AND INFLAMMATORY BIOMARKERS | Shereef Elmoamly | Received |
1074-P | EPCR SER219GLY POLYMORPHISM AND SUSCEPTIBILITY TO VENOUS THROMBOEMBOLISM IN THE POPULATION OF NORTH-WESTERN RUSSIA | Sergey Kapustin | Received |
1075-P | POLYMORPHISM OF VASCULAR TONE REGULATING GENES AND THE RISK OF VENOUS THROMBOEMBOLISM IN INDIVIDUALS WITH INHERITED THROMBOPHILIA | Anastasia Polyakova | Received |
1076-P | PROPHYLAXIS FOR VENOUS THROMBOEMBOLISM IN PATIENTS TREATED FOR ACUTE LYMPHOBLASTIC LEUKEMIA A SYSTEMATIC REVIEW | Mandy Lauw | Received |
1077-P | THROMBOPHILIAS INCIDENCE IN PATIENTS WITH FETAL LOSS IN LAST TRIMESTER AND EVALUATION OF THE EFFECTIVENESS OF TREATMENT | LAURA BERMEJO MARTÍNEZ | Received |
1079-P | THE NOVEL NOX INHIBITOR 2-ACETYLPHENOTHIAZINE IMPAIRS COLLAGEN-DEPENDENT THROMBUS FORMATION IN A GPVI-DEPENDENT MANNER | Dina Vara | Received |
1080-P | COMPARISON OF PATIENTS AND PHYSICIANS PERCEPTIONS OF PATIENTS BASELINE HEALTH-RELATED QUALITY OF LIFE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA | Isabelle Vande Broek | Received |
1081-P | PROFILING PATIENTS WITH HIGH-RISK MYELODYSPLASTIC SYNDROMES WHO PREFER TO RECEIVE SURVIVAL PROGNOSTIC INFORMATION. FINAL RESULTS FROM A LARGE INTERNATIONAL PROSPECTIVE COHORT OBSERVATIONAL STUDY | Fabio Efficace | Received |
1082-P | CROSS-CULTURAL DEVELOPMENT OF AN EORTC QUESTIONNAIRE FOR ASSESSING QUALITY OF LIFE IN CHRONIC MYELOID LEUKEMIA PATIENTS: THE EORTC QLQ-CML24 | Fabio Efficace | Received |
1084-P | HOW ACCURATE ARE PHYSICIANS IN ESTIMATING SYMPTOM SEVERITY AND HEALTH STATUS OF THEIR CHRONIC MYELOID LEUKEMIA PATIENTS? | Fabio Efficace | Received |
1085-P | PATTERNS OF FATIGUE IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA: A MULTICENTER OBSERVATIONAL STUDY | Fabio Efficace | Received |
1086-P | PAIN AND EMOTIONAL DISTRESS IN HEMATOLOGIC PATIENTS THROUGHOUT ALL PHASES OF DISEASE: RESULTS FROM A MULTIDISCIPLINARY RESEARCH TEAM IN MODENA UNIVERSITY HOSPITAL | Pierluigi Alfieri | Received |
1087-P | EFFICACY OF FENTANYL IN COMPARISON TO KETAMINE IN ANALGESIC EFFECT FOR HEMATOLOGY /ONCOLOGY PROCEDURES IN CHILDREN. A RANDOMIZED, DOUBLE-BLINDED, CROSSOVER, PLACEBO-CONTROLLED TRIAL | chanchai traivaree | Received |
1088-P | IS SCREENING FOR MALNUTRITION USEFUL IN OLDER PATIENTS WITH AGGRESSIVE HAEMATOLOGICAL MALIGNANCIES? | Anja Velghe | Received |
1089-P | IMPAIRED HEALTH-RELATED QUALITY OF LIFE IN ACUTE MYELOID LEUKEMIA SURVIVORS | Annemieke Leunis | Received |
1090-P | VALIDATION OF THE G8 IN OLDER PATIENTS WITH A HAEMATOLOGICAL MALIGNANCY | Anja Velghe | Received |
1091-P | PSYCHOLOGICAL ASSESSMENT OF SIBLINGS OF PATIENTS WITH CHILDHOOD CANCER: A FORGOTTEN GROUP | Ragab Iman | Received |
1092-P | HEALTH-RELATED QUALITY OF LIFE AMONG LONG-TERM SURVIVORS OF ADOLESCENT HODGKINS LYMPHOMA TREATED WITH PEDIATRIC APPROACH | Sergey Semochkin | Received |
1094-P | EARLY SUPPORTIVE/PALLIATIVE CARE INTEGRATED WITH STANDARD HEMATOLOGICAL CARE (SIMULTANEOUS CARE) IN MULTIPLE MYELOMA PATIENTS | FEDERICO VINCENZO | Received |
1095-P | WHAT DO PRELIMINARY ANALYSES HIGHLIGHT AS THE KEY FEARS AND WORRIES OF CHILDREN AND YOUNG PEOPLE WITH SICKLE CELL DISEASE AND WHAT CAN WE DO TO SUPPORT THEM? | Florence Bristow | Received |
1096-P | COMPREHENSIVE ANALYSIS OF CLINICALLY RELEVANT IMPROVEMENT IN PROGRESSION-FREE SURVIVAL IN HEMATOLOGIC MALIGNANCY FROM THE VIEWPOINT OF REVISED EMAS GUIDELINE ON ANTICANCER MEDICINAL PRODUCTS | Sumimasa Nagai | Received |
1097-P | DOES PREGNANCY INFLUENCE REMISSION RATE IN HEMATOLOGICAL MALIGNANCIES | Maria Vinogradova | Received |
1098-P | VALIDATION OF A COMPREHENSIVE HEALTH STATUS ASSESSMENT SCALE IN OLDER PATIENTS (= 65 YEARS) WITH HEMATOLOGICAL MALIGNANCES. GAH STUDY | Cristina Romera | Received |
1099-P | PSYCHOLOGICAL MORBIDITY FOLLOWING THE DIAGNOSIS OF A HAEMATOLOGICAL MALIGNANCY | Barry Kevane | Received |
1100-P | QUALITY OF LIFE OF THE PATIENTS WITH HEMATOLOGICAL MALIGNANCIES | LIUDMILA GRITSAY | Received |
13-16 June 2013 STOCKHOLM
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. |
||||
|